

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

PURDUE PHARMA L.P., et al.,

Debtors.¹

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

**Objection Deadline: May 17, 2021 at
5:00 p.m. ET**

**EIGHTEENTH MONTHLY FEE APPLICATION OF DECHERT LLP FOR
ALLOWANCE OF COMPENSATION FOR SERVICES RENDERED AND
REIMBURSEMENT OF EXPENSES AS COUNSEL TO THE DEBTORS AND
DEBTORS IN POSSESSION FOR THE PERIOD FROM
FEBRUARY 1, 2021 THROUGH FEBRUARY 28, 2021**

Name of Applicant:	Dechert LLP
Authorized to Provide Professional Services to:	Purdue Debtors and Debtors in Possession
Effective Date of Retention:	November 21, 2019 Nunc Pro Tunc to September 15, 2019
Period for which compensation and reimbursement is sought:	February 1, 2021 through February 28, 2021
Amount of compensation sought as actual, reasonable, and necessary:	\$599,966.34²
Eighty percent of actual, reasonable and necessary compensation:	\$479,973.07
Amount of expense reimbursement sought as actual, reasonable, and necessary:	\$1,674.14

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

² This amount reflects a reduction in fees in the amount of \$104,743.16 on account of voluntary discounts for aggregate fees as described in *Dechert LLP's First Notice of Increase in Hourly Rates for Litigation Services* [Docket No. 2221] (the "**Notice of Increased Litigation Fees**") and *Dechert LLP's Second Notice of Increase in Hourly Rates for Patent Services* [Docket No. 2342] (the "**Notice of Increased Patent Fees**").

This is a(n): ☒ Monthly ☐ Interim ☐ Final application.

Is this the first monthly application? ☐ Yes ☒ No

This application includes 81.0 hours with a discounted value of \$32,085.80 incurred in connection with the preparation of Fee Applications for the Debtors.

Compensation by Individual for Debtors for Litigation Services

Name of Professional Person	Position of the Applicant	Year of Obtaining License to Practice (if Applicable)	Hourly Billing Rate (Including Changes) ³	Total Billed Hours	Total Compensation
Sheila L Birnbaum	Partner	1965	1,500.00	103.80	155,700.00
Hayden A. Coleman	Partner	1985	1,050.00	163.10	171,255.00
Mara C. Cusker Gonzalez	Partner	2005	1,050.00	20.60	21,630.00
Paul A. LaFata	Partner	2007	975.00	20.60	20,085.00
Sara B. Roitman	Partner	2010	1,050.00	62.90	66,045.00
Jonathan S. Tam	Partner	2009	975.00	4.10	3,997.50
Shmuel Vasser	Partner	1988	1,250.00	30.20	37,750.00
Christopher R. Boisvert	Counsel	2009	975.00	5.50	5,362.50
Danielle Gentin Stock	Counsel	1999	975.00	84.50	82,387.50
Michelle K. Yeary	Counsel	1995	975.00	17.90	17,452.50
Noah Becker	Associate	2019	630.00	16.80	10,584.00
Alyssa C. Clark	Associate	2017	790.00	4.50	3,555.00
Rory M. Gledhill	Associate	2017	790.00	2.40	1,896.00
Mary H. Kim	Associate	2015	880.00	0.90	792.00
Jenna C. Newmark	Associate	2011	950.00	41.20	39,140.00
Katherine Norman	Associate	2019	630.00	6.10	3,843.00
Amisha Patel	Associate	2010	950.00	1.10	1,045.00
Theodore E. Yale	Associate	2017	790.00	10.40	8,216.00
Lindsay N. Zanello	Associate	2015	880.00	1.70	1,496.00
Nicholas C. Dean	Staff Attorney		465.00	26.10	12,136.50
Antonella Capobianco-Ranallo	Legal Asst	N/A	300.00	17.00	5,100.00
Jefferson Holder	Paralegal	N/A	300.00	1.20	360.00
Matthew B. Stone	Legal Asst	N/A	300.00	65.00	19,500.00
Danielle Torrice	Paralegal	N/A	300.00	0.20	60.00
Kurt Vinson	Paralegal	N/A	300.00	1.70	510.00

³ As described in the Notice of Increased Litigation Fees, these billing rates reflect voluntary discounts of 0% to 10% for senior partners, 5% to 12% for partners, 5% for counsel, and 5% to 7% for associates.

Denise Neris	Project Asst	N/A	175.00	6.00	1,050.00
Total				715.50	\$690,948.50
15% Volume Discount					(\$103,642.28)
Discounted Total					\$587,306.22
Total Amount Requested Herein					\$469,844.98

Compensation by Individual for Debtors for Patent Services

Name of Professional Person	Position of the Applicant	Year of Obtaining License to Practice (if Applicable)	Hourly Billing Rate (Including Changes)⁴	Total Billed Hours	Total Compensation
Samuel B. Abrams	Partner	1981	930.00	1.00	930.00
Blaine M. Hackman	Associate	2012	765.00	13.90	10,633.50
Seth E. Snyder	Patent Agent		630.00	2.90	1,827.00
Sherrice T. Breland	Legal Assistant	N/A	285.00	1.30	370.50
Total				19.10	\$13,761.00
8% Volume Discount⁵					(\$1,100.88)
Discounted Total					\$12,660.12
Total Amount Requested Herein					\$10,128.10

The blended hourly billing rate of professionals for all services provided during the Fee Period is \$816.73.

⁴ As described in Notice of Increased Patent Fees, these billing rates reflect voluntary discounts of 29% for partners, 23% for associates, 0% for paraprofessionals, and 8% to 15% for patent agents.

⁵ As described in the Notice of Increased Patent Fees, Dechert will apply an 8% discount for aggregate fees and this aggregate discount will apply to all timekeepers.

Compensation by Project Category for Debtors

Code	Project Category	Total Hours	Total Fees
B110	Case Administration	2.20	2,340.00
B160	Fee/Employment Applications	81.00	37,748.00
B165	Budgeting (case)	9.70	8,517.50
B260	Board of Directors Matters	6.40	9,390.00
B320	Plan and Disclosure Statement	1.80	2,250.00
L120	Analysis/Strategy	284.40	291,994.00
L130	Experts/Consultants	49.00	49,237.50
L140	Document/File Management	2.30	690.00
L160	Settlement/Non-Binding ADR	133.50	170,520.00
L190	Other Case Assessment, Development and Administration	6.80	1,290.00
L210	Pleadings	28.20	30,996.00
L220	Preliminary Injunctions/Provisional Remedies	2.50	2,587.50
L230	Court Mandated Conferences	13.80	15,420.00
L250	Other Written Motions and Submissions	1.60	1,264.00
L310	Written Discovery	13.20	13,320.00
L320	Document Production	27.40	23,397.50
L350	Discovery Motions	0.60	630.00
L390	Other Discovery	0.20	60.00
L440	Other Trial Preparation and Support	50.90	29,296.50
P260	Intellectual Property	19.10	13,761.00
Total		734.60	\$704,709.50⁶

⁶ This amount reflects the discounted billing rates but not the discounts for aggregate fees.

Expense Summary for Debtors

Expenses Category	Total Expenses
Consultants Fees ⁷	\$201.69
Court Costs	\$140.00
Docket Fees	\$40.41
Federal Express Charges	\$206.88
Filing Fees and Related	\$20.00
Legal Publication Expense	\$99.00
Lexis/Legal Research	\$706.67
Pacer Research Fees	\$221.60
Westlaw Search Fees	\$37.89
Total	\$1,674.14

⁷ These consultant fees are Ankura Consulting Group, LLC, a firm that manages a document hosting platform necessary for Dechert to provide legal services to the Debtors.

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

**PURDUE PHARMA L.P., *et al.*,

Debtors.¹**

Chapter 11

Case No. 19-23649 (RDD)

**(Jointly Administered)
Objection Deadline: May 17, 2021 at
5:00 p.m. ET**

**EIGHTEENTH MONTHLY FEE APPLICATION OF DECHERT LLP FOR
ALLOWANCE OF COMPENSATION FOR SERVICES RENDERED AND
REIMBURSEMENT OF EXPENSES AS COUNSEL TO THE DEBTORS AND
DEBTORS IN POSSESSION FOR THE PERIOD FROM
FEBRUARY 1, 2021 THROUGH FEBRUARY 28, 2021**

By this monthly fee application (the “**Application**”), pursuant to sections 330 and 331 of title 11 of the United States Code (the “**Bankruptcy Code**”) and Rule 2016 of the Federal Rules of Bankruptcy Procedure (the “**Bankruptcy Rules**”), Dechert LLP (“**Dechert**”) hereby moves this Court for discounted reasonable compensation for professional legal services rendered as attorneys to the Debtors in the amount of **\$479,973.07** together with reimbursement for actual and necessary expenses incurred in the amount of **\$1,674.14**, for the period commencing February 1, 2021 through and including February 28, 2021 (the “**Fee Period**”). In support of the Application, Dechert respectfully represents as follows:

¹ The Debtors in these cases, along with the last four digits of each Debtor’s registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors’ corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

1. Dechert was employed under a general retainer to represent the Debtors as bankruptcy counsel in connection with these chapter 11 cases pursuant to an order entered by this Court on November 21, 2019 [Docket No. 525] (the “**Retention Order**”). The Retention Order authorized Dechert to be compensated on an hourly basis and to be reimbursed for actual and necessary out-of-pocket expenses.

2. All services for which compensation is requested by Dechert were performed for or on behalf of the Debtors.

SUMMARY OF SERVICES RENDERED

3. Attached hereto as **Exhibit A** is a detailed statement of fees incurred during the Fee Period showing the amount of \$599,966.34,² of which \$479,973.07 is requested for fees in this Application. **Exhibit B** is a detailed statement of expenses paid during the Fee Period showing the amount of \$1,674.14 for reimbursement of expenses.

4. The services rendered by Dechert during the Fee Period are grouped into the categories set forth in **Exhibit A**. The attorneys and paralegals who rendered services relating to each category are identified, along with the number of hours for each individual and the total compensation sought for each category, in the attachments hereto.

DISBURSEMENTS

5. Dechert has incurred out-of-pocket disbursements during the Fee Period in the amount of \$1,674.14. This disbursement sum is broken down into categories of charges, including, among other things, document hosting and management, temporary employee expenses, expert consulting charges, telephone and telecopier toll and other charges, mail and

² This amount reflects a reduction in fees in the amount of \$104,743.16 on account of voluntary discounts for aggregate fees as described in *Dechert LLP’s First Notice of Increase in Hourly Rates for Litigation Services* [Docket No. 2221] (the “**Notice of Increased Litigation Fees**”) and *Dechert LLP’s Second Notice of Increase in Hourly Rates for Patent Services* [Docket No. 2342] (the “**Notice of Increased Patent Fees**”).

express mail charges, special or hand delivery charges, document processing, photocopying charges, charges for mailing supplies (including, without limitation, envelopes and labels) provided by Dechert to outside copying services for use in mass mailings, travel expenses, expenses for “working meals,” computerized research, and transcription costs.

6. A complete review of the expenses incurred for the Fee Period may be found in the attachments hereto as **Exhibit B**. To the extent such itemization is insufficient to satisfy the requirements of Rule 2016-1(a) of the Local Rules of Bankruptcy Practice and Procedure of the United States Bankruptcy Court for the Southern District of New York (the “**Local Rules**”), Dechert respectfully requests that the Court waive strict compliance with such rule.

7. Costs incurred for computer assisted research are not included in Dechert’s normal hourly billing rates and, therefore, are itemized and included in Dechert’s disbursements. Pursuant to Local Rule 2016-1, Dechert represents that its rate for duplication is \$.10 per page, there is no charge for incoming or outgoing telecopier transmissions, and there is no surcharge for computerized research.

VALUATION OF SERVICES

8. Attorneys and paraprofessionals of Dechert have expended a total of 989.20 hours in connection with the Debtors’ chapter 11 cases during the Fee Period.

9. The amount of time spent by each of these persons providing services to the Debtors for the Fee Period is fully set forth in detail in **Exhibit A**. These are Dechert’s discounted hourly rates for compensation in this case, as reflected in the Retention Application. The Discounted value of the services rendered by Dechert for the Fee Period as counsel for the Debtors in these cases under chapter 11 is \$599,966.34, of which \$479,973.07 is requested for fees in this Application.

10. Dechert believes that the time entries included in **Exhibit A** attached hereto and the expense breakdown set forth in **Exhibit B** attached hereto are in compliance with the requirements of Local Rule 2016-1.

11. In accordance with the factors enumerated in section 330 of the Bankruptcy Code, the amount requested is fair and reasonable given (a) the complexity of this case, (b) the time expended, (c) the nature and extent of the services rendered, (d) the value of such services, and (e) the costs of comparable services other than in a case under this title.

12. This Application covers the period of February 1, 2021 through and including February 28, 2021 with respect to the Debtors. Dechert has and will continue to perform additional necessary services for the Debtors subsequent to February 28, 2021, for which Dechert will file subsequent fee applications.

[Remainder of page left intentionally blank]

CONCLUSION

WHEREFORE, Dechert respectfully requests that (a) allowance be made to it in the sum of \$479,973.07 as compensation for necessary professional services rendered to the Debtors for the Fee Period, and the sum of \$1,674.14 for reimbursement of actual necessary costs and expenses incurred during the Fee Period, (b) such other further relief as this Court may deem just and proper.

Dated: May 3, 2021

Respectfully submitted,

/s/ Shmuel Vasser

Shmuel Vasser
DECHERT LLP
1095 Avenue of the Americas
New York, New York 10036
Telephone: (212) 698-3500
Facsimile: (212) 698-3599

Attorneys for Debtors and Debtors in Possession

**UNITED STATES BANKRUPTCY COURT
SOUTHERN DISTRICT OF NEW YORK**

In re:

**PURDUE PHARMA L.P., et al.,

Debtors.¹**

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

VERIFICATION OF SHMUEL VASSER

I, Shmuel Vasser, Esquire, hereby declare the following under penalty of perjury:

1. I am a Partner in the applicant firm, Dechert LLP, and have been admitted to the bar of New York since 1991.

2. I have personally performed some of the legal services rendered by Dechert LLP as counsel for the Debtors, and I am generally familiar with all other work performed on behalf of the Debtors by the lawyers and paraprofessionals in the firm.

3. The facts set forth in the foregoing Application are true and correct to the best of my knowledge, information and belief.

[Remainder of page left intentionally blank]

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

4. I hereby certify under 28 U.S.C. § 1746 that the foregoing is true and correct to the best of my knowledge, information, and belief.

Dated: May 3, 2021

Respectfully submitted,

/s/ Shmuel Vasser

Shmuel Vasser
DECHERT LLP
1095 Avenue of the Americas
New York, New York 10036
Telephone: (212) 698-3500
Facsimile: (212) 698-3599
shmuel.vasser@dechert.com

Attorneys for Debtors and Debtors in Possession

EXHIBIT A

Description of Legal Services



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

Purdue Pharma L.P.
201 Tresser Blvd.
Stamford, CT 06901

April 30, 2021
Invoice Number 1010012656

Firm Client Matter Number: 399631.178405

Client Name: Purdue Pharma L.P.
Matter Name: Mediation & Settlement, Claims Evaluation, and Operations
Electronic Billing Number: 20210003064

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL FEES FOR THIS INVOICE	626,789.50
Less 15% Discount	(94,018.43)
NET TOTAL FEES FOR THIS INVOICE.....	532,771.07
TOTAL DISBURSEMENTS THIS INVOICE	1,358.53

TOTAL AMOUNT DUE FOR THIS INVOICE	USD 534,129.60
--	-----------------------

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
B110 – Case Administration					
02/11/21	Shmuel Vasser	1.70	B110	A104	2,125.00
	Review docket updates/case status.				
02/26/21	Matthew Stone	0.20	B110	A105	60.00
	Email with Dechert team regarding March 1 hearing.				
02/27/21	Matthew Stone	0.20	B110	A101	60.00
	Arrange telephonic access for attorneys at March 1 hearing.				
B110 SUBTOTAL HOURS AND FEES:		2.10			2,245.00
B260 – Board of Directors Matters					
02/02/21	Sheila Birnbaum	1.20	B260	A109	1,800.00
	Attend Purdue Special Committee Meeting.				
02/03/21	Sheila Birnbaum	2.00	B260	A109	3,000.00
	Attend Purdue Board meeting.				
02/03/21	Danielle Gentin Stock	0.40	B260	A109	390.00
	Attend Purdue Board meeting for Monitor report.				
02/19/21	Sheila Birnbaum	1.50	B260	A109	2,250.00
	Attend Purdue Board Meeting.				
02/24/21	Sheila Birnbaum	1.30	B260	A109	1,950.00
	Attend Purdue Board Meeting.				
B260 SUBTOTAL HOURS AND FEES:		6.40			9,390.00
B320 – Plan and Disclosure Statement					
02/25/21	Shmuel Vasser	1.00	B320	A104	1,250.00
	Review draft proposed confirmation timeline, issues regarding plan and disclosure statement (1.0).				
02/25/21	Shmuel Vasser	0.80	B320	A105	1,000.00
	Internal discussions regarding status, issues, confirmation timeline (0.8).				
B320 SUBTOTAL HOURS AND FEES:		1.80			2,250.00
L120 – Analysis/Strategy					
02/01/21	Sheila Birnbaum	1.50	L120	A104	2,250.00
	Review background materials for monitor selection (1.5).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 3

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/01/21	Hayden Coleman	0.70	L120	A106	735.00
	Communicate with Dechert team, DPW, and client regarding Neonatal Abstinence Syndrome Guardians' Motion for class certification in MDL.				
02/01/21	Hayden Coleman	2.10	L120	A104	2,205.00
	Review materials and emails from DPW regarding Neonatal Abstinence Syndrome Ad Hoc Committee (2.1).				
02/01/21	Hayden Coleman	0.80	L120	A105	840.00
	Emails with Dechert team regarding proposed monitors.				
02/01/21	Hayden Coleman	1.70	L120	A104	1,785.00
	Review opinion and order denying Neonatal Abstinence Syndrome Guardians' Motion for class certification in MDL (1.4); review and revise summary of order denying Neonatal Abstinence Syndrome guardians' motion for class certification in MDL (0.3).				
02/01/21	Mara Cusker Gonzalez	0.70	L120	A103	735.00
	Draft and revise claims adjustment analysis for public and private claims valuation.				
02/01/21	Paul LaFata	0.60	L120	A104	585.00
	Analyze class certification ruling issued in MDL.				
02/01/21	Sara Roitman	1.40	L120	A104	1,470.00
	Review and revise claims analysis for private, public, and commercial claimants.				
02/01/21	Sara Roitman	0.60	L120	A105	630.00
	Communicate with Dechert team regarding claims strategy.				
02/01/21	Rory Gledhill	2.40	L120	A103	1,896.00
	Draft analysis of court's order denying NAS Guardian's motion for class certification.				
02/01/21	Danielle Gentin Stock	1.20	L120	A106	1,170.00
	Correspond with client regarding Monitor findings and filing of report (0.9); confer with client regarding Monitor findings and fact checks (0.3).				
02/01/21	Danielle Gentin Stock	0.20	L120	A104	195.00
	Review correspondence regarding MDL ruling denying Neonatal Abstinence Syndrome certification.				
02/01/21	Danielle Gentin Stock	0.40	L120	A105	390.00
	Correspond internally regarding Monitor interviews and materials.				
02/01/21	Danielle Gentin Stock	0.50	L120	A104	487.50
	Review and fact-check Monitor findings.				
02/01/21	Danielle Gentin Stock	0.40	L120	A108	390.00
	Correspond with consenting/dissenting states regarding upcoming interviews (0.1); correspond with co-counsel regarding filing of Monitor report (0.2); correspond with Monitor candidate regarding interview (0.1).				
02/02/21	Sheila Birnbaum	0.40	L120	A105	600.00
	Telephone conference with D. Stock regarding monitor selection.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 4

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/02/21	Sheila Birnbaum	2.70	L120	A108	4,050.00
	Prepare for monitors interview call (0.7); attend monitor interviews with various groups (2.0).				
02/02/21	Sheila Birnbaum	0.70	L120	A104	1,050.00
	Review draft monitor report with review of emails regarding same (0.7).				
02/02/21	Sheila Birnbaum	0.30	L120	A106	450.00
	Telephone conference with Dechert and Purdue about choosing monitor (0.3).				
02/02/21	Hayden Coleman	0.90	L120	A106	945.00
	Participate in weekly coordination with client and retained counsel (0.9).				
02/02/21	Mara Cusker Gonzalez	0.60	L120	A103	630.00
	Revise analysis regarding claim valuation adjustment.				
02/02/21	Mara Cusker Gonzalez	0.60	L120	A107	630.00
	Confer with bankruptcy counsel and litigation counsel regarding claims valuation adjustment analysis.				
02/02/21	Sara Roitman	0.50	L120	A104	525.00
	Review and analyze commercial and private claimant abatement plans and summary regarding same.				
02/02/21	Sara Roitman	1.00	L120	A107	1,050.00
	Confer with bankruptcy counsel regarding strategy for claims valuation and valuation analysis.				
02/02/21	Sara Roitman	1.20	L120	A104	1,260.00
	Analyze Neonatal Abstinence Syndrome claimants' claim valuation in light of class certification denial for impact on overall claims analysis.				
02/02/21	Jonathan Tam	0.90	L120	A107	877.50
	Prepare for (0.2) and attend conference with co-counsel regarding claims analyses (0.7).				
02/02/21	Jenna Newmark	1.60	L120	A104	1,520.00
	Review/analyze NAS class certification decision (0.8); review prior memoranda for call with Davis Polk team (0.8).				
02/02/21	Jenna Newmark	0.70	L120	A107	665.00
	Participate in videoconference with DPW regarding NAS class certification decision (0.7).				
02/02/21	Danielle Gentin Stock	0.10	L120	A104	97.50
	Review correspondence regarding Neonatal Abstinence Syndrome certification denial.				
02/02/21	Danielle Gentin Stock	0.70	L120	A105	682.50
	Confer internally regarding Monitor interviews and report (0.5); correspond internally regarding Monitor interviews (0.2).				
02/02/21	Danielle Gentin Stock	1.20	L120	A103	1,170.00
	Prepare talking points related to Monitor's findings (1.2).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 5

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/02/21	Danielle Gentin Stock	3.70	L120	A108	3,607.50
	Confer with candidate regarding interview process (0.5); prepare for and participate on Monitor candidate interviews (2.5); correspond with Monitor regarding availability to report to Board (0.2); correspond with co-counsel regarding Monitor interviews (0.1); correspond with Monitor candidate in follow-up to interview (0.2); correspond with bankruptcy committee representatives regarding Monitor interview follow-up (0.2).				
02/02/21	Danielle Gentin Stock	0.50	L120	A106	487.50
	Confer with client regarding Monitor interviews (0.3); correspond with client regarding Monitor findings (0.2).				
02/02/21	Danielle Gentin Stock	0.90	L120	A106	877.50
	Participate on client update call with co-counsel.				
02/03/21	Sheila Birnbaum	0.50	L120	A108	750.00
	Telephone conference with representative of consenting states regarding monitor (0.5).				
02/03/21	Sheila Birnbaum	0.40	L120	A106	600.00
	Telephone conference with Purdue regarding monitor (0.4).				
02/03/21	Sheila Birnbaum	0.40	L120	A104	600.00
	Review emails regarding choosing monitor (0.4).				
02/03/21	Hayden Coleman	0.40	L120	A104	420.00
	Review summary of Neonatal Abstinence Syndrome claims (0.4).				
02/03/21	Hayden Coleman	1.60	L120	A107	1,680.00
	Conference call with DPW and Dechert teams regarding Neonatal Abstinence Syndrome Ad Hoc Committee requests (0.5); participate in WebEx with Cornerstone, DPW, and Dechert regarding claims administration (0.8); emails with Cornerstone, Dechert and DPW regarding revised claims estimations for non-personal injury private claimants (0.3).				
02/03/21	Hayden Coleman	2.70	L120	A104	2,835.00
	Review proposed revised plan term sheet (2.7).				
02/03/21	Mara Cusker Gonzalez	1.00	L120	A108	1,050.00
	Attend meeting with outside consultants regarding public and private claims analysis.				
02/03/21	Sara Roitman	1.00	L120	A107	1,050.00
	Confer with consultants and bankruptcy counsel regarding personal injury claims analysis and strategy.				
02/03/21	Sara Roitman	0.80	L120	A104	840.00
	Analyze revised valuation of public, private, and commercial claimants.				
02/03/21	Danielle Gentin Stock	0.20	L120	A106	195.00
	Correspond with client regarding Board of Directors call (0.2).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 6

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/03/21	Danielle Gentin Stock	0.20	L120	A106	195.00
	Correspond with client regarding Monitor findings.				
02/03/21	Danielle Gentin Stock	0.20	L120	A107	195.00
	Correspond with co-counsel regarding filings for Monitor report and approvals.				
02/03/21	Danielle Gentin Stock	0.40	L120	A106	390.00
	Confer with client regarding Monitor report and selection (0.4).				
02/04/21	Sheila Birnbaum	0.50	L120	A104	750.00
	Review monitor issues (0.5).				
02/04/21	Hayden Coleman	0.50	L120	A105	525.00
	Conference calls with Dechert team regarding planning and strategy.				
02/04/21	Hayden Coleman	2.50	L120	A104	2,625.00
	Review updated analysis of Neonatal Abstinence Syndrome and non-hospital provider claims (0.4); research potential enforcement mechanism for trust agreements with public and private groups (2.1).				
02/04/21	Mara Cusker Gonzalez	0.50	L120	A103	525.00
	Revise draft claims valuation adjustment analysis in conjunction with updated analysis from outside consultant.				
02/04/21	Sara Roitman	1.30	L120	A105	1,365.00
	Communicate with Dechert team regarding claims analysis and valuation (.8) and regarding trust oversight and appeals process (.5).				
02/04/21	Danielle Gentin Stock	0.50	L120	A105	487.50
	Correspond internally regarding monitor selection (0.3); correspond internally regarding monitor report filing (0.2).				
02/04/21	Danielle Gentin Stock	0.40	L120	A104	390.00
	Review correspondence from client regarding filing of Monitor report (0.2); correspond internally regarding pro se complaint (0.2).				
02/05/21	Sheila Birnbaum	0.30	L120	A106	450.00
	Telephone conference with Purdue regarding choosing monitor.				
02/05/21	Sheila Birnbaum	0.80	L120	A108	1,200.00
	Telephone conference with various groups to choose monitor (0.5); telephone conference with Ad Hoc states representative regarding monitor (0.3).				
02/05/21	Hayden Coleman	1.50	L120	A105	1,575.00
	Conference call with Dechert team regarding monitors and enforcement of abatement requirements under plan (0.7); emails with Dechert team regarding plan documents and trust agreements to build in monitoring and enforcement provisions (0.8).				
02/05/21	Hayden Coleman	3.90	L120	A104	4,095.00
	Review and analyze plan documents and trust agreements regarding monitoring and enforcement provisions (3.9).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 7

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/05/21	Hayden Coleman	0.50	L120	A107	525.00
	Participate in WebEx with DPW and Dechert regarding open claims assessment issues (0.5).				
02/05/21	Hayden Coleman	0.70	L120	A108	735.00
	Participate in WebEx with Cornerstone, Dechert and DPW regarding open claims assessment issues (0.7).				
02/05/21	Mara Cusker Gonzalez	1.50	L120	A108	1,575.00
	Prepare for (.6) and attend meetings (.9) with bankruptcy counsel, litigation counsel, and expert consultants regarding claims valuation analysis and strategy.				
02/05/21	Sara Roitman	1.30	L120	A104	1,365.00
	Review issues regarding public, private, and commercial claimants' claim strategy (1.3).				
02/05/21	Sara Roitman	1.20	L120	A108	1,260.00
	Communicate with bankruptcy counsel and consultants regarding public, private, and commercial claimants' claim strategy.				
02/05/21	Jenna Newmark	0.50	L120	A104	475.00
	Review draft schedule for plan filing, confirmation hearing and related deadlines (0.5).				
02/05/21	Danielle Gentin Stock	0.60	L120	A107	585.00
	Correspond with Monitor candidate regarding selection process (0.2); participate on call with various committees to discuss Monitor selection (0.4).				
02/05/21	Danielle Gentin Stock	1.00	L120	A104	975.00
	Review materials relevant to onboarding Monitor (0.5); review agreement to onboard monitor (0.5).				
02/05/21	Danielle Gentin Stock	1.20	L120	A106	1,170.00
	Confer with client regarding next steps of onboarding Monitor (0.2); correspond with client regarding materials to onboard Monitor (1.0).				
02/08/21	Hayden Coleman	0.90	L120	A103	945.00
	Draft proposed monitor and enforcement provisions.				
02/08/21	Hayden Coleman	1.20	L120	A104	1,260.00
	Review draft restructuring plan.				
02/08/21	Danielle Gentin Stock	0.10	L120	A105	97.50
	Correspond internally regarding monitor selection.				
02/08/21	Danielle Gentin Stock	0.10	L120	A106	97.50
	Correspond with client regarding monitor selection.				
02/08/21	Danielle Gentin Stock	1.00	L120	A104	975.00
	Review enforcement of abatement trust provisions (0.8); review correspondence regarding co-defendant treatment under the Plan (0.2).				
02/08/21	Danielle Gentin Stock	0.70	L120	A105	682.50
	Confer internally regarding potential abatement monitor (0.7).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 8

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/09/21	Sheila Birnbaum	1.00	L120	A107	1,500.00
	Attend weekly telephone conference with Purdue lawyers regarding status of litigation (1.0).				
02/09/21	Hayden Coleman	4.90	L120	A104	5,145.00
	Review and comment on restructuring plan's abatement and enforcement provisions (4.9).				
02/09/21	Hayden Coleman	1.10	L120	A106	1,155.00
	Prepare for and participate in strategy call with client and retained counsel (1.1).				
02/09/21	Hayden Coleman	2.10	L120	A104	2,205.00
	Review and comment on emails and charts with Cornerstone, DPW, and Dechert regarding personal injury, hospitals, and third-party payors claims estimation (2.1).				
02/09/21	Sara Roitman	1.30	L120	A105	1,365.00
	Communicate with Dechert team regarding monitor appointment.				
02/09/21	Sara Roitman	1.00	L120	A104	1,050.00
	Review and analyze valuation assumptions for private, public, and commercial claimants regarding plan confirmation.				
02/09/21	Sara Roitman	1.30	L120	A105	1,365.00
	Communicate with Dechert team regarding claims strategy and valuation.				
02/09/21	Shmuel Vasser	1.60	L120	A104	2,000.00
	Review materials regarding impact of joint defense agreements (1.6).				
02/09/21	Shmuel Vasser	1.50	L120	A102	1,875.00
	Conduct research regarding impact of joint defense agreements (1.5).				
02/09/21	Shmuel Vasser	0.40	L120	A105	500.00
	Emails with Dechert team regarding impact of joint defense agreements (.4).				
02/09/21	Jenna Newmark	3.20	L120	A103	3,040.00
	Draft memorandum regarding personal injury claimants' valuation (3.2).				
02/09/21	Danielle Gentin Stock	0.10	L120	A105	97.50
	Correspond internally regarding co-counsel MDL query.				
02/09/21	Danielle Gentin Stock	0.40	L120	A105	390.00
	Correspond internally regarding provision of an abatement monitor (0.2); confer internally regarding monitor for abatement trusts (0.2).				
02/09/21	Danielle Gentin Stock	0.10	L120	A104	97.50
	Review correspondence regarding Monitor selection.				
02/09/21	Danielle Gentin Stock	1.00	L120	A107	975.00
	Participate on client update call with co-counsel.				
02/09/21	Danielle Gentin Stock	1.10	L120	A104	1,072.50
	Review materials concerning monitor for abatement trusts (1.1).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 9

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/09/21	Danielle Gentin Stock	0.80	L120	A103	780.00
	Draft and revise proposed language concerning monitor for abatement trusts (0.8).				
02/10/21	Hayden Coleman	1.30	L120	A107	1,365.00
	Emails with DPW regarding monitoring and enforcement provisions under the plan and trust documents (1.3).				
02/10/21	Hayden Coleman	4.30	L120	A104	4,515.00
	Review letter to U.S. Trustee and cases cited therein (1.9); review and comment on response to letter to U.S. Trustee (1.2); review DOJ claims (1.2).				
02/10/21	Hayden Coleman	1.20	L120	A108	1,260.00
	Emails with Cornerstone, Dechert, and DPW teams regarding claim estimates (1.2).				
02/10/21	Hayden Coleman	0.60	L120	A104	630.00
	Review and comment on updated municipalities and tribes claims estimates (0.6).				
02/10/21	Paul LaFata	0.10	L120	A108	97.50
	Confer with discovery vendor regarding service termination.				
02/10/21	Sara Roitman	1.00	L120	A104	1,050.00
	Review and revise proposed language regarding monitor for settlement abatement funds.				
02/10/21	Sara Roitman	1.30	L120	A107	1,365.00
	Communicate with bankruptcy counsel regarding claims analysis and plan confirmation strategy.				
02/10/21	Sara Roitman	0.80	L120	A105	840.00
	Communicate with Dechert team regarding claims analysis and strategy for monitor structure.				
02/10/21	Shmuel Vasser	1.10	L120	A105	1,375.00
	Email correspondence with Dechert team regarding joint defense agreement implications.				
02/10/21	Jenna Newmark	1.00	L120	A104	950.00
	Review correspondence and updated analyses for claims valuation analysis (1.0).				
02/10/21	Christopher Boisvert	0.30	L120	A107	292.50
	Correspond with Wyoming local counsel regarding Wyoming law.				
02/10/21	Danielle Gentin Stock	0.60	L120	A106	585.00
	Correspond with client regarding Monitor selection (0.6).				
02/10/21	Danielle Gentin Stock	0.40	L120	A105	390.00
	Correspond internally regarding Plan provisions/personal injury related claims and issues.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 10

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/11/21	Hayden Coleman	2.20	L120	A107	2,310.00
	Prepare for and participate in Webex with Dechert and DPW regarding approach to claims valuation (0.9); email to/from DPW regarding Co-defendant treatment under the plan (0.8); conference call with DPW and creditors regarding cross indemnifications in certain distributor and vendor contracts (0.5).				
02/11/21	Mara Cusker Gonzalez	0.70	L120	A107	735.00
	Confer with litigation counsel regarding claims valuation strategy (.4); prepare for discussions with bankruptcy counsel and outside consultants regarding same (.3).				
02/11/21	Sara Roitman	0.80	L120	A104	840.00
	Review and revise proposed plan language regarding definition of Neonatal Abstinence Syndrome claimants.				
02/11/21	Sara Roitman	1.20	L120	A105	1,260.00
	Communicate with Dechert team regarding personal injury and commercial claims valuation.				
02/11/21	Sara Roitman	0.40	L120	A107	420.00
	Communicate with co-Defendants regarding case and claim tracking issues.				
02/11/21	Sara Roitman	0.70	L120	A104	735.00
	Review and revise proposed plan language regarding settlement Monitor.				
02/11/21	Shmuel Vasser	0.50	L120	A104	625.00
	Review filed letter regarding joint defense agreement issues.				
02/11/21	Jenna Newmark	1.80	L120	A103	1,710.00
	Draft and revise memoranda summarizing revised analysis of claims (1.8).				
02/11/21	Jenna Newmark	0.60	L120	A107	570.00
	Participate in videoconference with Davis Polk team regarding claims analysis (0.6).				
02/11/21	Theodore Yale	6.30	L120	A102	4,977.00
	Conduct research regarding hospital and third-party payor claims.				
02/11/21	Christopher Boisvert	0.30	L120	A107	292.50
	Correspond with Sackler counsel regarding McCallister unsealing proceedings.				
02/11/21	Danielle Gentin Stock	0.70	L120	A104	682.50
	Review and analyze proposed Plan language related to distributors.				
02/11/21	Danielle Gentin Stock	0.10	L120	A107	97.50
	Correspond with co-counsel regarding Monitor replacement.				
02/11/21	Danielle Gentin Stock	0.20	L120	A105	195.00
	Correspond internally regarding proposed Plan language/personal injury related issues.				
02/11/21	Danielle Gentin Stock	0.10	L120	A106	97.50
	Correspond with client regarding new Monitor.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 11

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/12/21	Sheila Birnbaum	1.00	L120	A107	1,500.00
	Telephone conference with Davis Polk, Dechert, and experts regarding personal injury claims (0.5); telephone conference with Davis Polk regarding bankruptcy plan/personal injury claims issues (0.5).				
02/12/21	Sheila Birnbaum	1.00	L120	A104	1,500.00
	Review draft plan for reorganization/personal injury related claims issues (1.0).				
02/12/21	Hayden Coleman	3.60	L120	A104	3,780.00
	Review DOJ proof of claims for Medicaid/Medicare, VA, and tribal lien claims (1.8); evaluate and comment on Purdue plan treatment of Distributors indemnity claims (1.8).				
02/12/21	Hayden Coleman	3.90	L120	A107	4,095.00
	Conference call with DPW and Dechert regarding claims analysis and planning (0.5); prepare for and participate in weekly call with Cornerstone, DPW, and Dechert (1.0); conference call with Dechert and DPW regarding DOJ proofs of claim (0.6); emails and conferences with Dechert and DPW regarding Purdue plan treatment of Distributors indemnity claims (1.2); emails with DPW, Dechert and client regarding privilege log redactions (0.6).				
02/12/21	Hayden Coleman	0.80	L120	A103	840.00
	Draft plan language to address NAACP diversity considerations.				
02/12/21	Mara Cusker Gonzalez	0.80	L120	A108	840.00
	Prepare for (.2) and attend meeting (.6) with bankruptcy counsel, litigation counsel, and outside consultants regarding public and private claims valuation.				
02/12/21	Sara Roitman	1.30	L120	A104	1,365.00
	Review and analyze public, private, and commercial claimants' proofs of claim.				
02/12/21	Jenna Newmark	2.50	L120	A104	2,375.00
	Review prior correspondence and memoranda for claims analysis (2.5).				
02/12/21	Danielle Gentin Stock	0.60	L120	A105	585.00
	Correspond internally regarding claims analysis (0.1); correspond internally regarding Plan language regarding same (0.5).				
02/12/21	Danielle Gentin Stock	0.20	L120	A106	195.00
	Correspond with client regarding Plan language/personal injury related issues.				
02/12/21	Danielle Gentin Stock	0.30	L120	A104	292.50
	Review and analyze correspondence relating to school districts claims.				
02/12/21	Danielle Gentin Stock	0.50	L120	A107	487.50
	Correspond with monitor candidate regarding monitorship (0.1); correspond with client regarding filings relating to the Monitor (0.4).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 12

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/14/21	Sara Roitman	2.50	L120	A104	2,625.00
	Review, analyze, and revise school districts' proposed trust agreement and other claimants' trust agreements regarding plan confirmation and claim valuation.				
02/15/21	Hayden Coleman	2.30	L120	A107	2,415.00
	Emails with DPW regarding certain revisions to defined terms in plan (0.3); communicate with DPW and Wiggin regarding inquiries from Neonatal Abstinence Syndrome Ad Hoc group (0.6); conferences and correspondence with Dechert team and DPW regarding same (0.8); WebEx with DPW and Dechert regarding revisions to claims analysis (0.6).				
02/15/21	Hayden Coleman	1.00	L120	A105	1,050.00
	Plan for (0.1) and participate in meeting with Dechert team regarding comments to claims analysis (0.9).				
02/15/21	Mara Cusker Gonzalez	0.70	L120	A107	735.00
	Confer with litigation counsel and bankruptcy counsel regarding claims valuation strategy and analysis (.7).				
02/15/21	Paul LaFata	0.20	L120	A104	195.00
	Review updates regarding case proceedings.				
02/15/21	Sara Roitman	1.40	L120	A105	1,470.00
	Communicate with Dechert team regarding claims valuation and analysis.				
02/15/21	Sara Roitman	1.00	L120	A107	1,050.00
	Communicate with bankruptcy counsel regarding plan confirmation filings/personal injury claims issues.				
02/15/21	Jenna Newmark	3.50	L120	A103	3,325.00
	Revise memoranda regarding claims analysis (3.5).				
02/15/21	Jenna Newmark	0.90	L120	A105	855.00
	Participate in telephone call with Dechert team regarding claims analysis (0.9).				
02/15/21	Jenna Newmark	0.60	L120	A107	570.00
	Participate in videoconference with Davis Polk team regarding claims analysis (0.6).				
02/15/21	Danielle Gentin Stock	0.50	L120	A107	487.50
	Confer with co-counsel regarding claims analysis.				
02/15/21	Danielle Gentin Stock	0.40	L120	A104	390.00
	Review correspondence regarding Ad Hoc Committee on Accountability filing (0.2); review correspondence regarding Neonatal Abstinence Syndrome Committee request (0.2).				
02/15/21	Danielle Gentin Stock	1.30	L120	A105	1,267.50
	Correspond internally regarding Plan term sheets/personal injury claims issues (0.2); correspond internally regarding claims analysis (0.2); confer internally regarding claims analysis (0.9).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 13

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/16/21	Sheila Birnbaum	0.70	L120	A107	1,050.00
	Telephone conference with Purdue legal team regarding status of litigation.				
02/16/21	Sheila Birnbaum	2.20	L120	A104	3,300.00
	Review materials on current plan/personal injury claims issues (0.6); review comments of other groups to draft plan/personal injury issues (0.8); review email comments to school district proposal and review proposal (0.8).				
02/16/21	Sheila Birnbaum	0.40	L120	A104	600.00
	Review issues regarding retention of monitor (0.4).				
02/16/21	Hayden Coleman	4.70	L120	A104	4,935.00
	Review and comment on draft of Plan of Reorganization/personal injury related issues (1.2); review and comment on draft of the NewCo/TopCo Governance Term Sheet (1.7); review summary of McKinsey proceeding in NY AG action (0.6); review personal injury related comments to draft plan from creditor groups (1.2).				
02/16/21	Hayden Coleman	0.70	L120	A107	735.00
	Plan for and participate in weekly principals coordinating committee call with client and retained counsel.				
02/16/21	Paul LaFata	0.10	L120	A104	97.50
	Analyze order on attorney-client privilege in MDL.				
02/16/21	Sara Roitman	1.40	L120	A105	1,470.00
	Communicate with Dechert team regarding school district term sheet and proposed trust, claims analysis, and plan confirmation strategy.				
02/16/21	Jenna Newmark	1.80	L120	A103	1,710.00
	Draft claims analysis regarding valuation.				
02/16/21	Theodore Yale	1.00	L120	A102	790.00
	Conduct research regarding personal injury awards.				
02/16/21	Danielle Gentin Stock	0.40	L120	A106	390.00
	Confer with client regarding onboarding new Monitor (0.2); correspond with client regarding new Monitor (0.2).				
02/16/21	Danielle Gentin Stock	0.10	L120	A105	97.50
	Correspond internally regarding onboarding Monitor.				
02/16/21	Danielle Gentin Stock	0.40	L120	A104	390.00
	Review and comment on proposed trust agreement (0.3); review correspondence on Plan updates (0.1).				
02/17/21	Sheila Birnbaum	0.30	L120	A104	450.00
	Review emails regarding monitor retention.				
02/17/21	Hayden Coleman	0.40	L120	A105	420.00
	Conference with Dechert team regarding Omnibus Hearing.				
02/17/21	Hayden Coleman	0.90	L120	A106	945.00
	Emails and conference call with client regarding local counsel considerations (0.6); emails with client, DPW, and Dechert regarding adversary proceeding (0.3).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 14

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/17/21	Hayden Coleman	2.80	L120	A107	2,940.00
	Conference call with DPW and Dechert teams regarding School District claims (0.5); WebEx with Cornerstone, Dechert, and DPW regarding personal injury, third party payor, and hospital claims (1.0); emails with Dechert and DPW teams regarding Neonatal Abstinence Syndrome Committee meet and confer follow up on certain databases (1.3).				
02/17/21	Hayden Coleman	0.40	L120	A104	420.00
	Review and comment on report on NY status conference.				
02/17/21	Sara Roitman	0.90	L120	A105	945.00
	Communicate with Dechert team regarding claims analysis and strategy (.4) and related plan confirmation issues (.5).				
02/17/21	Theodore Yale	3.10	L120	A102	2,449.00
	Conduct research regarding personal injury awards.				
02/17/21	Danielle Gentin Stock	1.00	L120	A107	975.00
	Confer with co-counsel and experts regarding claims analysis.				
02/18/21	Sheila Birnbaum	1.10	L120	A104	1,650.00
	Review monitor materials (0.3); review plan draft/personal injury related issues (0.8).				
02/18/21	Hayden Coleman	0.20	L120	A106	210.00
	Emails with client regarding Bloyd and Fitch adversary proceeding.				
02/18/21	Hayden Coleman	2.80	L120	A102	2,940.00
	Conduct research regarding potential purchasers of Purdue assets (2.8).				
02/18/21	Hayden Coleman	1.80	L120	A105	1,890.00
	Emails and conference calls with Dechert team regarding potential purchasers of Purdue assets (1.8).				
02/18/21	Mara Cusker Gonzalez	0.50	L120	A107	525.00
	Confer with litigation counsel regarding claims valuation strategy.				
02/18/21	Sara Roitman	1.30	L120	A104	1,365.00
	Analyze claims estimates for creditor groups.				
02/18/21	Noah Becker	2.70	L120	A102	1,701.00
	Conduct research regarding potential purchasers of Purdue assets (2.7).				
02/18/21	Noah Becker	0.60	L120	A105	378.00
	Calls with H. Coleman regarding potential purchasers of Purdue assets research (0.6).				
02/18/21	Jenna Newmark	0.50	L120	A104	475.00
	Review and analyze research regarding personal injury jury verdicts for claims analysis.				
02/18/21	Jenna Newmark	1.30	L120	A105	1,235.00
	Telephone call with S. Roitman and M. Cusker-Gonzalez regarding status of claims analysis (0.3); draft email correspondence to team regarding claims analysis (0.2); participate in telephone call with S. Roitman regarding personal injury claims analysis (0.8).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 15

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/18/21	Danielle Gentin Stock	0.50	L120	A105	487.50
	Correspond internally regarding reviewing and assembling materials for onboarding Monitor.				
02/18/21	Danielle Gentin Stock	0.80	L120	A106	780.00
	Correspond with client regarding preparation for Monitor call (0.3); correspond with client regarding materials for onboarding Monitor (0.5).				
02/18/21	Danielle Gentin Stock	0.80	L120	A107	780.00
	Confer with Monitor candidate regarding selection (0.1); confer with Monitor and client regarding on-boarding (0.5); review correspondence with co-counsel regarding filings for the Monitor (0.2).				
02/18/21	Danielle Gentin Stock	0.60	L120	A103	585.00
	Draft and revise agenda for initial call with Monitor.				
02/19/21	Sheila Birnbaum	0.40	L120	A104	600.00
	Review materials for monitor and emails (0.4).				
02/19/21	Hayden Coleman	5.80	L120	A104	6,090.00
	Review and analyze plan terms and supporting structures as it pertains to personal injury claims and classes (2.7); review correspondence from NAACP (0.4); review sales presentation to Purdue (0.9); review and revise memorandum regarding acquisition offer (1.8).				
02/19/21	Mara Cusker Gonzalez	1.00	L120	A108	1,050.00
	Attend meeting with bankruptcy counsel, litigation counsel, and expert consultants regarding public and private claims valuation.				
02/19/21	Sara Roitman	1.30	L120	A105	1,365.00
	Communicate with Dechert team regarding claims strategy and claims analysis for personal injury, commercial claimants, and public entities.				
02/19/21	Sara Roitman	1.00	L120	A104	1,050.00
	Analyze claims values for different claimant groups.				
02/19/21	Noah Becker	3.50	L120	A103	2,205.00
	Draft memorandum regarding potential purchasers of Purdue assets (3.5).				
02/19/21	Noah Becker	0.90	L120	A105	567.00
	Call with H. Coleman regarding potential purchasers of Purdue assets (0.5); call with H. Coleman and D. Gentin Stock regarding same (0.4).				
02/19/21	Danielle Gentin Stock	0.40	L120	A106	390.00
	Correspond with client regarding Monitor agreements (0.2); correspond internally regarding Monitor meeting (0.2).				
02/19/21	Danielle Gentin Stock	5.50	L120	A104	5,362.50
	Draft, review and revise memorandum regarding potential alternative to the Plan/personal injury claims issues.				
02/19/21	Danielle Gentin Stock	1.30	L120	A105	1,267.50
	Confer internally regarding memorandum on potential proposed alternative to the Plan/personal injury issues (0.8); correspond internally regarding memorandum on potential proposed alternative to the Plan (0.5).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 16

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/20/21	Noah Becker	4.10	L120	A103	2,583.00
	Revise potential purchaser research memorandum (4.1).				
02/20/21	Noah Becker	0.20	L120	A105	126.00
	Call with D. Gentin Stock regarding potential purchaser research memorandum.				
02/20/21	Danielle Gentin Stock	0.50	L120	A105	487.50
	Confer internally regarding memorandum on potential proposed alternative to the Plan/Litigation issues (0.2); correspond internally regarding same (0.3).				
02/20/21	Danielle Gentin Stock	4.00	L120	A103	3,900.00
	Revise memorandum regarding potential alternative to the Plan/litigation issues impact.				
02/21/21	Noah Becker	0.50	L120	A103	315.00
	Revise memorandum regarding potential purchaser (0.5).				
02/21/21	Noah Becker	0.10	L120	A105	63.00
	Call with D. Gentin Stock regarding memorandum on potential purchaser of Purdue assets (0.1).				
02/21/21	Danielle Gentin Stock	0.50	L120	A103	487.50
	Revise memorandum regarding potential alternative to the Plan/personal injury issues.				
02/21/21	Danielle Gentin Stock	0.20	L120	A105	195.00
	Confer and correspond internally regarding memorandum on potential proposed alternative to the Plan/personal injury issues.				
02/22/21	Sheila Birnbaum	0.30	L120	A104	450.00
	Review NY litigation update (0.3).				
02/22/21	Hayden Coleman	1.30	L120	A107	1,365.00
	Emails with Dechert and DPW regarding governmental liens on personal injury claims (0.9); emails with Dechert and DPW teams regarding Neonatal Abstinence Syndrome group (0.4).				
02/22/21	Paul LaFata	0.20	L120	A104	195.00
	Analyze ruling on privilege log disclosures and protective order.				
02/22/21	Danielle Gentin Stock	0.20	L120	A106	195.00
	Correspond with client regarding orientation for Monitor.				
02/22/21	Danielle Gentin Stock	0.20	L120	A105	195.00
	Correspond internally regarding Personal Injury claims.				
02/22/21	Danielle Gentin Stock	0.90	L120	A106	877.50
	Confer with client regarding case status and updates.				
02/22/21	Danielle Gentin Stock	1.60	L120	A104	1,560.00
	Review and analyze materials for the Monitor.				
02/23/21	Sheila Birnbaum	0.50	L120	A107	750.00
	Telephone conference with Purdue litigation team regarding case status.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 17

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/23/21	Sheila Birnbaum	1.00	L120	A104	1,500.00
	Review materials for monitor orientation (1.0).				
02/23/21	Hayden Coleman	0.70	L120	A107	735.00
	Participate in update and strategy call with client and retained counsel.				
02/23/21	Hayden Coleman	0.90	L120	A105	945.00
	Emails with Dechert team regarding federal liens on personal injury claims (0.9).				
02/23/21	Sara Roitman	1.60	L120	A104	1,680.00
	Review claims analysis for personal injury, commercial, and public claims (1.0); review literature regarding inflation values for personal injury claims (0.6).				
02/23/21	Noah Becker	0.40	L120	A105	252.00
	Call with S. Birnbaum, H. Coleman, D. Gentin Stock to discuss memorandum on potential purchaser of Purdue assets (0.4).				
02/23/21	Noah Becker	1.20	L120	A103	756.00
	Revise memorandum on potential purchaser of Purdue assets (1.2).				
02/23/21	Mary Kim	0.30	L120	A103	264.00
	Summarize work product on NAS abatement plan.				
02/23/21	Danielle Gentin Stock	0.40	L120	A105	390.00
	Correspond internally regarding Monitor meeting.				
02/23/21	Danielle Gentin Stock	0.20	L120	A107	195.00
	Communicate with Monitor candidate regarding retention decision.				
02/23/21	Danielle Gentin Stock	0.80	L120	A105	780.00
	Confer internally regarding alternative to Plan/personal injury issues (0.5); correspond internally regarding potential alternative/objection to Plan regarding personal injury issues (0.3).				
02/23/21	Danielle Gentin Stock	1.50	L120	A103	1,462.50
	Draft and revise analysis of Plan alternative/objection regarding personal injury issues.				
02/23/21	Danielle Gentin Stock	0.30	L120	A106	292.50
	Correspond with client regarding Monitor meeting.				
02/23/21	Danielle Gentin Stock	0.50	L120	A106	487.50
	Participate on client update call with co-counsel.				
02/23/21	Danielle Gentin Stock	2.00	L120	A104	1,950.00
	Draft, revise and review materials for the incoming Monitor.				
02/24/21	Hayden Coleman	0.50	L120	A107	525.00
	Conference call with Dechert and DPW teams regarding outstanding issues and strategy.				
02/24/21	Hayden Coleman	1.10	L120	A108	1,155.00
	Prepare for (0.4) and participate in conference call with expert and Dechert team regarding value of personal injury claims (0.7).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 18

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/24/21	Hayden Coleman	0.20	L120	A105	210.00
	Emails with Dechert team regarding lien administrators (0.2).				
02/24/21	Mara Cusker Gonzalez	0.70	L120	A107	735.00
	Attend meetings with bankruptcy counsel and litigation counsel regarding claims valuation and disclosure strategy.				
02/24/21	Mara Cusker Gonzalez	0.30	L120	A104	315.00
	Review and analyze updated claims valuation analyses in preparation for meetings with bankruptcy and litigation counsel.				
02/24/21	Noah Becker	2.60	L120	A103	1,638.00
	Revise and finalize memorandum on potential Purdue asset purchaser (2.6).				
02/24/21	Lindsay Zanello	0.40	L120	A104	352.00
	Review documents regarding Purdue's market share (.4).				
02/24/21	Lindsay Zanello	0.20	L120	A105	176.00
	Communicate internally regarding Purdue's market share (.2).				
02/24/21	Danielle Gentin Stock	1.00	L120	A106	975.00
	Prepare for and confer with client regarding upcoming Monitor meeting (0.5); correspond with client regarding agenda and materials for meeting with Monitor (0.5).				
02/24/21	Danielle Gentin Stock	0.30	L120	A107	292.50
	Correspond with client and co-counsel regarding Plan query.				
02/24/21	Danielle Gentin Stock	0.70	L120	A104	682.50
	Revise agenda for meeting with Monitor.				
02/24/21	Danielle Gentin Stock	0.70	L120	A105	682.50
	Confer internally regarding revisions to memorandum on objection/response to Plan alternative re personal injury issues (0.7).				
02/24/21	Danielle Gentin Stock	2.50	L120	A103	2,437.50
	Draft and revise memorandum on objection/response to Plan alternative.				
02/25/21	Sheila Birnbaum	3.50	L120	A104	5,250.00
	Review issues of class action voting rights (0.7); review comments to draft bankruptcy plan re personal injury issues (0.8); review materials from personal injury claims representative regarding liens (0.7); review memorandum on consent rights (0.5); review draft plan and comments/personal injury issues (0.8).				
02/25/21	Sheila Birnbaum	0.60	L120	A107	900.00
	Telephone conference with Davis Polk regarding voting rights (0.3); telephone conference with Davis Polk regarding distributors issues (0.3).				
02/25/21	Hayden Coleman	1.20	L120	A107	1,260.00
	Meet and confer with Neonatal Abstinence Syndrome Committee (0.4); emails with Dechert, DPW, and Wiggins teams regarding Neonatal Abstinence Syndrome Committee (0.8).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 19

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/25/21	Hayden Coleman	1.10	L120	A107	1,155.00
	Review and respond to emails with DPW, Dechert, and personal injury groups (0.7); review and respond to emails with client and DPW regarding Bloyd and Fitch adversary proceeding (0.4).				
02/25/21	Hayden Coleman	0.30	L120	A104	315.00
	Review order issued in McCallister case (0.3).				
02/25/21	Paul LaFata	0.40	L120	A103	390.00
	Draft revisions to regulatory correspondence.				
02/25/21	Paul LaFata	0.20	L120	A107	195.00
	Confer with client and co-defense counsel regarding revisions to regulatory correspondence.				
02/25/21	Paul LaFata	0.10	L120	A108	97.50
	Confer with discovery vendor regarding revisions to regulatory correspondence.				
02/25/21	Sara Roitman	0.60	L120	A107	630.00
	Confer with client and bankruptcy co-counsel regarding class voting issues and strategy regarding same (.6).				
02/25/21	Sara Roitman	1.00	L120	A104	1,050.00
	Analyze issues regarding personal injury claims and valuation estimates.				
02/25/21	Danielle Gentin Stock	2.50	L120	A104	2,437.50
	Review, analyze, draft materials for Monitor orientation.				
02/25/21	Danielle Gentin Stock	0.20	L120	A106	195.00
	Confer with client regarding Monitor orientation.				
02/26/21	Sheila Birnbaum	0.40	L120	A107	600.00
	Telephone conference with Davis Polk regarding progress update on plan.				
02/26/21	Hayden Coleman	0.70	L120	A108	735.00
	Participate in WebEx with personal injury claim representatives regarding plan updates.				
02/26/21	Hayden Coleman	0.50	L120	A106	525.00
	Conference call with client regarding Bloyd and Fitch adversary proceeding.				
02/26/21	Hayden Coleman	1.40	L120	A107	1,470.00
	Conferences and emails with Dechert and DPW teams regarding McKinsey indemnification materials (1.4).				
02/26/21	Mara Cusker Gonzalez	0.50	L120	A107	525.00
	Attend meeting with bankruptcy counsel regarding valuation and disclosure status.				
02/26/21	Paul LaFata	0.10	L120	A107	97.50
	Confer with co-counsel regarding revisions to vendor retainer.				
02/26/21	Sara Roitman	0.60	L120	A106	630.00
	Confer with client regarding strategy for personal injury complaints and plan confirmation strategy.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 20

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/26/21	Jonathan Tam	0.50	L120	A107	487.50
	Confer with co-counsel and experts regarding claims analyses (0.5).				
02/26/21	Christopher Boisvert	0.40	L120	A107	390.00
	Correspond with client and Sackler family counsel regarding McCallister order appointing discovery commissioner.				
02/26/21	Danielle Gentin Stock	3.50	L120	A101	3,412.50
	Prepare outlines, agenda and materials for meeting with Monitor.				
02/26/21	Danielle Gentin Stock	0.30	L120	A107	292.50
	Confer with co-counsel regarding claims analysis.				
L120 SUBTOTAL HOURS AND FEES:		274.90			282,320.50

L130 – Experts/Consultants

02/01/21	Jenna Newmark	0.30	L130	A104	285.00
	Review/revise summary of public claims analysis (0.3)				
02/03/21	Hayden Coleman	1.40	L130	A104	1,470.00
	Review and comment on Cornerstone's revised claims estimations for non-personal injury private claimants (1.4).				
02/03/21	Jonathan Tam	0.50	L130	A108	487.50
	Strategize and confer with co-counsel and experts regarding claims analyses (0.5).				
02/03/21	Jenna Newmark	0.80	L130	A107	760.00
	Participate in video call with Cornerstone and Davis Polk team regarding claims valuation analysis (0.8).				
02/05/21	Jenna Newmark	0.90	L130	A107	855.00
	Participate in videoconference with Davis Polk team regarding claims analysis (0.5); participate in videoconference with Davis Polk team and Cornerstone regarding claims analysis (0.4).				
02/08/21	Sheila Birnbaum	0.50	L130	A108	750.00
	Telephone conference with Purdue and financial experts regarding sale of company.				
02/08/21	Hayden Coleman	1.10	L130	A108	1,155.00
	Emails with Cornerstone regarding Tribe and Municipalities claims.				
02/08/21	Jenna Newmark	2.00	L130	A104	1,900.00
	Review and analyze updated claims analyses from Cornerstone.				
02/11/21	Hayden Coleman	0.60	L130	A108	630.00
	Conference call with personal injury valuation expert regarding trust agreement.				
02/11/21	Sara Roitman	1.00	L130	A108	1,050.00
	Confer with bankruptcy counsel and consultants regarding claims valuation and analysis.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 21

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/11/21	Jenna Newmark	2.30	L130	A104	2,185.00
	Review and analyze research regarding revised claims valuation (2.3).				
02/11/21	Jenna Newmark	0.60	L130	A108	570.00
	Participate in telephone call with expert regarding analysis of personal injury claims (0.6).				
02/12/21	Sara Roitman	2.10	L130	A108	2,205.00
	Communicate with consultants and bankruptcy counsel regarding claims valuation and strategy.				
02/12/21	Jenna Newmark	1.60	L130	A107	1,520.00
	Participate in videoconference with Davis Polk team regarding claims analysis (0.6); participate in videoconference with Davis Polk and Cornerstone teams regarding claims analysis (1.0).				
02/12/21	Danielle Gentin Stock	1.60	L130	A108	1,560.00
	Discuss claims analysis with co-counsel and experts (1.6).				
02/14/21	Jenna Newmark	1.10	L130	A104	1,045.00
	Review email correspondence regarding analysis of personal injury claims (1.1).				
02/15/21	Mara Cusker Gonzalez	0.50	L130	A108	525.00
	Discussions with expert consultants regarding claims valuation strategy and analysis (.5).				
02/17/21	Mara Cusker Gonzalez	1.00	L130	A108	1,050.00
	Attend meeting with bankruptcy counsel and outside consultants regarding claims valuation and adjustment strategies.				
02/17/21	Sara Roitman	1.00	L130	A108	1,050.00
	Confer with consultants and bankruptcy counsel regarding claims strategy.				
02/17/21	Jonathan Tam	1.30	L130	A108	1,267.50
	Prepare for (0.3) and confer with experts and co-counsel regarding claims analyses (1.0).				
02/17/21	Jenna Newmark	1.40	L130	A104	1,330.00
	Review and analyze Cornerstone claims analysis (1.4).				
02/18/21	Hayden Coleman	0.30	L130	A107	315.00
	Emails with Dechert and DPW teams regarding Cornerstone assignments.				
02/18/21	Sara Roitman	1.00	L130	A108	1,050.00
	Confer with consultant regarding claims analysis for personal injury claims.				
02/19/21	Mara Cusker Gonzalez	0.50	L130	A104	525.00
	Review and analyze updated claims adjustment models from expert consultants.				
02/19/21	Jenna Newmark	1.70	L130	A104	1,615.00
	Review and analyze updated analysis from Cornerstone of claims (1.7).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 22

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/19/21	Jenna Newmark	0.60	L130	A105	570.00
	Participate in telephone call with S. Roitman and M. Cusker-Gonzalez regarding updated analysis from Cornerstone (0.6).				
02/19/21	Jenna Newmark	1.20	L130	A108	1,140.00
	Participate in videoconference with Cornerstone and Davis Polk teams regarding updated claims analysis (1.2).				
02/19/21	Danielle Gentin Stock	1.00	L130	A108	975.00
	Confer with co-counsel and experts regarding claims analysis.				
02/23/21	Hayden Coleman	0.60	L130	A108	630.00
	Conference call with Dechert and retained expert regarding personal injury claims.				
02/23/21	Hayden Coleman	3.90	L130	A104	4,095.00
	Review and analyze briefing and expert reports in MDL regarding Neonatal Abstinence Syndrome (3.9).				
02/23/21	Mara Cusker Gonzalez	0.50	L130	A104	525.00
	Review and analyze updated model and draft analyses from expert consultants regarding claims valuation (0.5).				
02/23/21	Mara Cusker Gonzalez	0.30	L130	A107	315.00
	Confer with litigation counsel regarding updated model and draft analyses from expert consultants regarding claims valuation (0.3).				
02/23/21	Sara Roitman	1.00	L130	A108	1,050.00
	Confer with consultant regarding personal injury claims analysis (0.6); prepare regarding same (0.4).				
02/23/21	Jenna Newmark	2.30	L130	A104	2,185.00
	Review and analyze updated analysis of claims from Cornerstone (2.3).				
02/23/21	Jenna Newmark	0.50	L130	A108	475.00
	Participate in telephone call with expert D. Greenspan regarding updated analysis of claims from Cornerstone (0.5).				
02/23/21	Jenna Newmark	1.00	L130	A103	950.00
	Draft email correspondence regarding Cornerstone analysis (1.0).				
02/24/21	Sara Roitman	2.50	L130	A104	2,625.00
	Analyze values from consultants regarding personal injury, third party payor, and hospital claims.				
02/24/21	Jenna Newmark	0.50	L130	A107	475.00
	Participate in telephone call with Davis Polk team regarding claim analysis (0.5).				
02/24/21	Jenna Newmark	0.60	L130	A103	570.00
	Draft summary of call with D. Greenspan (0.6).				
02/24/21	Danielle Gentin Stock	0.50	L130	A107	487.50
	Confer with co-counsel regarding expert claims analysis.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 23

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/26/21	Hayden Coleman	0.70	L130	A108	735.00
	Participate in WebEx with Dechert and DPW regarding Cornerstone analysis (0.7).				
02/26/21	Hayden Coleman	1.00	L130	A108	1,050.00
	Participate in WebEx with Cornerstone, DPW and Dechert regarding Cornerstone analysis (1.0).				
02/26/21	Mara Cusker Gonzalez	0.70	L130	A108	735.00
	Attend meeting with expert consultants regarding valuation analysis and strategy.				
02/26/21	Sara Roitman	1.20	L130	A108	1,260.00
	Communicate with consultants and co-counsel regarding strategy for claims values for valuation purposes for personal injury, public, and commercial claimants.				
02/26/21	Jenna Newmark	0.90	L130	A107	855.00
	Participate in videoconference with Cornerstone and Davis Polk teams to discuss claims analysis (0.5); participate in videoconference with Davis Polk team to discuss claims analysis (0.4).				
02/28/21	Jenna Newmark	0.40	L130	A104	380.00
	Review and analyze updated personal injury claims analysis from Cornerstone (0.4).				
L130 SUBTOTAL HOURS AND FEES:		49.00			49,237.50
L140 – Document/File Management					
02/01/21	Antonella Capobianco-Ranallo	1.30	L140	A110	390.00
	Review new filings and communicate with team leaders regarding same.				
02/02/21	Antonella Capobianco-Ranallo	0.10	L140	A110	30.00
	Review new filings and communicate with team leaders regarding same.				
L140 SUBTOTAL HOURS AND FEES:		1.40			420.00
L160 – Settlement/Non-Binding ADR					
02/01/21	Sheila Birnbaum	1.00	L160	A104	1,500.00
	Review insurance responses regarding email (0.3); review emails regarding settlement proposals (0.7).				
02/01/21	Sheila Birnbaum	2.30	L160	A108	3,450.00
	Telephone conference with mediator regarding settlement (0.5); telephone conference with various creditor groups and financial advisers regarding settlement proposal (1.0); telephone conference with representative of Ad Hoc Committee of Consenting States, Purdue and Davis Polk regarding settlement proposal (0.8).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 24

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/01/21	Sheila Birnbaum	2.00	L160	A106	3,000.00
	Telephone conference with M. Huebner and representative of Ad Hoc Consenting States regarding settlement (1.0); telephone conference with R. Silbert regarding settlement issues (0.5); telephone conference with M. Kesselman, M. Huebner, T. Baker regarding settlement issues (0.5).				
02/01/21	Sara Roitman	1.00	L160	A104	1,050.00
	Analyze implications for Purdue settlement regarding denial of Neonatal Abstinence Syndrome class certification motion.				
02/01/21	Sara Roitman	0.60	L160	A105	630.00
	Communicate with Dechert team regarding mediation developments.				
02/02/21	Sheila Birnbaum	1.70	L160	A104	2,550.00
	Review materials on settlement proposal (0.5); review emails regarding settlement issues (0.4); review materials of Ad Hoc Committees regarding settlement and emails regarding same (0.8).				
02/02/21	Sheila Birnbaum	2.20	L160	A106	3,300.00
	Telephone conference with Purdue lawyers regarding settlement issues (0.5); telephone conference with R. Silbert regarding settlement issues (0.4); telephone conference with T. Baker regarding settlement (0.3); telephone conference with M. Kesselman, M. Huebner, and T. Baker regarding settlement (1.0).				
02/02/21	Hayden Coleman	0.60	L160	A107	630.00
	Respond to inquiries from DPW regarding draft settlement agreement with Neonatal Abstinence Syndrome ad hoc committee (0.6).				
02/02/21	Hayden Coleman	2.40	L160	A104	2,520.00
	Review and comment on revised chart of open mediation issues (0.5); review draft settlement agreement with Neonatal Abstinence Syndrome ad hoc committee (1.9).				
02/02/21	Danielle Gentin Stock	0.10	L160	A104	97.50
	Review correspondence regarding abatement query.				
02/03/21	Sheila Birnbaum	0.40	L160	A107	600.00
	Telephone conference with Davis Polk and Dechert regarding settlement issues (0.4).				
02/03/21	Sheila Birnbaum	0.80	L160	A106	1,200.00
	Telephone conferences with R. Silbert regarding settlement issues (0.8).				
02/03/21	Sheila Birnbaum	2.80	L160	A104	4,200.00
	Review revised draft term sheet and emails regarding same (1.6); review materials regarding NAACP settlement (0.7).				
02/03/21	Hayden Coleman	2.10	L160	A104	2,205.00
	Review and comment on draft settlement agreements with third-party payors and hospital groups.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 25

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/03/21	Hayden Coleman	0.60	L160	A105	630.00
	Emails with Dechert team regarding McKinsey settlement.				
02/03/21	Hayden Coleman	0.50	L160	A107	525.00
	Conference call with DPW and Dechert teams regarding open mediation issues (0.5).				
02/03/21	Danielle Gentin Stock	0.30	L160	A107	292.50
	Confer with co-counsel regarding status of mediation and next steps.				
02/04/21	Sheila Birnbaum	0.70	L160	A108	1,050.00
	Telephone conference with representative of NAACP regarding settlement.				
02/04/21	Sheila Birnbaum	3.30	L160	A108	4,950.00
	Telephone conference with Purdue, Davis Polk and financial advisors regarding draft term sheet (1.0); telephone conference with Purdue and Ad Hoc committee and financial experts regarding draft term sheet (1.3); telephone conference with R. Silbert regarding settlement issues (0.7); telephone conference with M. Huebner regarding settlement issues (0.3).				
02/04/21	Sheila Birnbaum	2.80	L160	A104	4,200.00
	Review materials for NAACP regarding settlement (0.5); review draft of term sheet and issues identified (0.8); review McKinsey settlement and contracts (0.8); review updates regarding McKinsey settlement (0.7).				
02/04/21	Hayden Coleman	1.80	L160	A104	1,890.00
	Review and respond to emails to/from client analyzing McKinsey settlement and discussing potential ramification on Purdue (1.8).				
02/04/21	Paul LaFata	0.40	L160	A104	390.00
	Analyze reporting of third party settlement of claims.				
02/04/21	Sara Roitman	1.00	L160	A104	1,050.00
	Analyze issues regarding McKinsey settlement and implications for Purdue regarding same.				
02/04/21	Sara Roitman	0.70	L160	A105	735.00
	Communicate with Dechert team regarding various settlement and mediation strategy issues.				
02/05/21	Sheila Birnbaum	0.30	L160	A105	450.00
	Telephone conference with Dechert team regarding term sheet.				
02/05/21	Sheila Birnbaum	0.70	L160	A107	1,050.00
	Telephone conference with Davis Polk regarding term sheet and settlement.				
02/05/21	Hayden Coleman	0.80	L160	A107	840.00
	Emails with client, DPW and Dechert regarding McKinsey settlement summary (0.4); respond to emails from Skadden regarding consenting/dissenting state breakdown (0.4).				
02/05/21	Sara Roitman	1.80	L160	A105	1,890.00
	Communicate with Dechert team regarding mediation and settlement status (.4), McKinsey settlement (.5), proposed plan settlement language (.6), and settlement appeals process (.3).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 26

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/05/21	Sara Roitman	1.50	L160	A104	1,575.00
	Analyze issues regarding proposed appeals process and monitor for abatement funds for settlement purposes (.7); review precedent regarding same (.8).				
02/05/21	Danielle Gentin Stock	0.60	L160	A102	585.00
	Research response to co-counsel query regarding settlement.				
02/05/21	Danielle Gentin Stock	0.40	L160	A105	390.00
	Confer internally regarding analysis of term sheets.				
02/05/21	Danielle Gentin Stock	0.20	L160	A107	195.00
	Correspond with co-counsel regarding settlement query (0.2).				
02/06/21	Sheila Birnbaum	1.30	L160	A106	1,950.00
	Review and respond to multiple emails to/from client regarding settlement and term sheet.				
02/07/21	Sheila Birnbaum	1.00	L160	A106	1,500.00
	Review and respond to multiple emails to/from client regarding settlement and term sheet.				
02/08/21	Sheila Birnbaum	0.50	L160	A105	750.00
	Telephone conference with Dechert team regarding draft term sheet.				
02/08/21	Sheila Birnbaum	1.20	L160	A108	1,800.00
	Telephone conference with mediator regarding settlement issues (0.4); telephone conference with representative of Ad Hoc committee of consenting states regarding settlement issues (0.8).				
02/08/21	Sheila Birnbaum	4.70	L160	A104	7,050.00
	Review and respond to emails regarding settlement (0.5); review additions to term sheet regarding releases (0.4); review new proposal for sale of Purdue assets and emails regarding same (0.8); review draft of settlement plan (1.0); review settlement issues regarding school districts (0.3); review draft of plan for settlement (0.8); review materials for AG issues (0.5); review materials for monitoring abatement issues (0.4).				
02/08/21	Hayden Coleman	0.40	L160	A106	420.00
	Emails with client regarding insurance issues relating to McKinsey settlement (0.2).				
02/08/21	Hayden Coleman	0.50	L160	A105	525.00
	Conference call with Dechert team regarding mediation update.				
02/08/21	Hayden Coleman	2.30	L160	A107	2,415.00
	Conference call with DPW regarding Bloyd and Fink Adversary Proceeding (0.4); emails with Dechert and DPW teams regarding monitoring and enforcement mechanism in plan and trust agreements (1.6); emails with retained counsel and Neonatal Abstinence Syndrome Ad Hoc Committee regarding settlement (0.3).				
02/08/21	Sara Roitman	1.80	L160	A103	1,890.00
	Draft proposed appeal process for settlement agreement and abatement funds.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 27

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/08/21	Sara Roitman	0.60	L160	A106	630.00
	Confer with client regarding strategy for handling complaint objecting to settlement structure and prepare regarding same.				
02/08/21	Sara Roitman	1.60	L160	A105	1,680.00
	Communicate with Dechert team regarding mediation status (.5), plan confirmation strategy/personal injury issues (.6), and settlement release language (.5).				
02/08/21	Danielle Gentin Stock	0.80	L160	A105	780.00
	Confer internally regarding settlement negotiations (0.8).				
02/09/21	Sheila Birnbaum	0.50	L160	A107	750.00
	Telephone conference with Purdue, Davis Polk, and T. Baker regarding settlement issues.				
02/09/21	Sheila Birnbaum	1.20	L160	A108	1,800.00
	Telephone conference with representative of NAACP regarding settlement (0.5); telephone conference with representative of Ad Hoc Committee of Consenting States regarding settlement issues (0.7).				
02/09/21	Sheila Birnbaum	0.50	L160	A107	750.00
	Telephone conference with Davis Polk regarding settlement issues (0.5).				
02/09/21	Sheila Birnbaum	1.60	L160	A104	2,400.00
	Review materials on settlement with Sacklers (0.8); review documents and emails regarding potential sale of Purdue assets (0.8).				
02/09/21	Sara Roitman	2.30	L160	A104	2,415.00
	Review and revise plan confirmation language regarding settlement monitor and processes for ensuring compliance with settlement terms.				
02/10/21	Sheila Birnbaum	4.30	L160	A104	6,450.00
	Review materials, slides and emails on revised asset bid (0.8); review materials on claims analysis regarding settlement (0.5); review materials and emails regarding letter to trustee (0.8); review issues of co-defendant treatment and settlement under settlement plan (0.8); review emails regarding Neonatal Abstinence Syndrome plaintiffs class motion for settlement (0.6); review DOJ claims regarding settlement (0.8).				
02/10/21	Sara Roitman	0.90	L160	A105	945.00
	Communicate with Dechert team regarding claims analysis and strategy regarding use of settlement funds.				
02/11/21	Sheila Birnbaum	0.80	L160	A104	1,200.00
	Review distribution settlement proposal and emails regarding same.				
02/11/21	Sheila Birnbaum	0.50	L160	A106	750.00
	Telephone conference with M. Kesselman regarding settlement issues (0.5)				
02/11/21	Hayden Coleman	0.40	L160	A106	420.00
	Emails to/from client and DPW regarding materials for confidentiality and privileges.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 28

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/11/21	Hayden Coleman	5.60	L160	A104	5,880.00
	Review and evaluate materials for confidentiality and privileges (0.3); review and comment on draft correspondence to Neonatal Abstinence Syndrome committee responding to request for birth mothers information (0.3); review and comment on memo regarding trends in personal injury verdicts and settlements (1.4); review and comment on plan provision regarding Monitor and voluntary injunction (1.7); review and analyze cross indemnifications in certain distributor and vendor contracts (1.9).				
02/11/21	Sara Roitman	0.30	L160	A104	315.00
	Analyze insurance statements in litigation for jurisdictional purposes regarding settlement.				
02/11/21	Sara Roitman	0.30	L160	A107	315.00
	Communicate with client and insurance co-counsel regarding insurance jurisdictional issues regarding settlement.				
02/12/21	Sheila Birnbaum	0.60	L160	A108	900.00
	Telephone conference with school districts representative regarding settlement issues.				
02/12/21	Sheila Birnbaum	1.00	L160	A106	1,500.00
	Telephone conference with M. Kesselman, M. Huebner, and T. Baker regarding settlement issues (0.7); telephone conference with T. Baker and R. Silbert regarding settlement (0.3).				
02/12/21	Sheila Birnbaum	2.30	L160	A104	3,450.00
	Review analysis of bid for Purdue assets (0.7); review and revise plan regarding settlement (0.8); review emails and materials on settlement issues (0.8).				
02/15/21	Sheila Birnbaum	1.40	L160	A104	2,100.00
	Review school districts settlement proposal and emails regarding same (0.8); review emails and proposal for Sackler settlement (0.6).				
02/15/21	Hayden Coleman	4.00	L160	A104	4,200.00
	Review and comment on School District Trust settlement proposals (2.2); review revised creditor trust agreements (1.8).				
02/16/21	Sheila Birnbaum	0.50	L160	A105	750.00
	Telephone conference with Dechert team regarding settlement issues.				
02/16/21	Sheila Birnbaum	1.20	L160	A109	1,800.00
	Attend Purdue Special Committee meeting regarding settlement.				
02/16/21	Sheila Birnbaum	0.80	L160	A106	1,200.00
	Telephone conference with T. Baker regarding settlement issues (0.5); telephone conference with M. Kesselman regarding settlement issues (0.3).				
02/16/21	Hayden Coleman	1.90	L160	A107	1,995.00
	Call with DPW, Dechert and Wiggins regarding Neonatal Abstinence Syndrome group's inquiries and preparation for meet and confer (0.4); emails and conference call with DPW and Dechert team regarding School Districts' proposed trust structure (1.5).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 29

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/16/21	Hayden Coleman	0.40	L160	A108	420.00
	Participate in Neonatal Abstinence Syndrome Committee meet and confer.				
02/16/21	Danielle Gentin Stock	0.50	L160	A105	487.50
	Confer internally regarding trust/settlement documents.				
02/16/21	Danielle Gentin Stock	0.70	L160	A106	682.50
	Confer with client and co-counsel regarding settlement updates.				
02/17/21	Sheila Birnbaum	1.20	L160	A108	1,800.00
	Telephone conference with representative of NAACP regarding settlement (0.5); telephone conference with representative of consenting states regarding settlement (0.7).				
02/17/21	Sheila Birnbaum	2.10	L160	A106	3,150.00
	Telephone conference with R. Silbert and T. Baker regarding settlement issues (0.3); telephone conference with Davis Polk and T. Baker regarding settlement issues (0.7); telephone conference with Davis Polk and Purdue and T. Baker regarding settlement issues (1.1).				
02/17/21	Sheila Birnbaum	0.30	L160	A107	450.00
	Telephone conference with Davis Polk regarding school district settlement.				
02/17/21	Sara Roitman	0.40	L160	A105	420.00
	Communicate with Dechert team regarding mediation strategy (.4).				
02/18/21	Sheila Birnbaum	1.90	L160	A104	2,850.00
	Telephone conference with Gov. Bullock regarding monitor orientation (0.5); telephone conference with representatives of Neonatal Abstinence Syndrome claimants regarding settlement (0.8); telephone conference with representative of consenting states regarding settlement (0.6).				
02/18/21	Sheila Birnbaum	0.30	L160	A104	450.00
	Review NAACP materials regarding settlement (0.3).				
02/19/21	Sheila Birnbaum	1.10	L160	A104	1,650.00
	Review NAACP settlement proposal and telephone conference with R. Silbert regarding same (0.7); review Neonatal Abstinence Syndrome claimants settlement proposal (0.4).				
02/19/21	Hayden Coleman	1.90	L160	A105	1,995.00
	Conferences and correspondence with Dechert team regarding sale of Purdue assets.				
02/20/21	Sheila Birnbaum	0.30	L160	A104	450.00
	Review letter on settlement from UCC and emails regarding same.				
02/20/21	Sheila Birnbaum	0.40	L160	A106	600.00
	Telephone conference with M. Huebner regarding settlement issues.				
02/22/21	Sheila Birnbaum	0.50	L160	A106	750.00
	Telephone conference with T. Baker regarding settlement.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 30

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/22/21	Sheila Birnbaum	2.80	L160	A104	4,200.00
	Review Neonatal Abstinence Syndrome Committee memorandum regarding settlement (0.5); review emails regarding DOJ settlement issues (0.3); review draft plan regarding settlement and emails regarding same (0.8); review materials on settlement proposal regarding sale (0.8); review materials for monitor and e-mails regarding same (0.4).				
02/22/21	Hayden Coleman	1.30	L160	A105	1,365.00
	Conferences and correspondence with Dechert team regarding potential sale of Purdue assets.				
02/22/21	Hayden Coleman	4.20	L160	A104	4,410.00
	Review and revise memorandum regarding potential sale of Purdue assets (4.2).				
02/23/21	Sheila Birnbaum	3.00	L160	A104	4,500.00
	Review draft plan and issues regarding settlement (0.7); review arguments from various groups to draft plans/personal injury issues (0.8); review memorandum and materials on potential Purdue sale of assets (0.8); review distribution proposal for settlement and emails regarding same (0.7).				
02/23/21	Sheila Birnbaum	0.90	L160	A107	1,350.00
	Telephone conference with M. Kesselman and Davis Polk regarding drafting settlement term sheet.				
02/23/21	Sheila Birnbaum	0.50	L160	A108	750.00
	Telephone conference with NAACP representative regarding settlement.				
02/23/21	Hayden Coleman	1.70	L160	A105	1,785.00
	Conference calls with Dechert team regarding asset sales memorandum and related issues (1.7).				
02/23/21	Hayden Coleman	1.10	L160	A103	1,155.00
	Revise asset sales memorandum.				
02/23/21	Hayden Coleman	0.50	L160	A104	525.00
	Review and analyze materials regarding personal injury verdicts and settlement trends (0.5).				
02/23/21	Hayden Coleman	0.50	L160	A107	525.00
	Conference call with retained counsel regarding Neonatal Abstinence Syndrome demand.				
02/24/21	Sheila Birnbaum	2.70	L160	A104	4,050.00
	Review bankruptcy timeline (0.3); review memorandum on settlement consent rights (0.3); review comments of Ad Hoc Committee to confirmation plan (1.3); review settlement materials and comments on draft plan (0.8).				
02/24/21	Sheila Birnbaum	1.80	L160	A108	2,700.00
	Telephone conference with Ad Hoc Committee representative regarding settlement (0.5); telephone conference with representatives of Ad Hoc Committees and Davis Polk regarding settlement issues (0.8); telephone conference with representatives of personal injury claimants and Ad Hoc Committee regarding settlement (0.5).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 31

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/24/21	Sheila Birnbaum	0.50	L160	A109	750.00
	Attend Purdue Special Committee Meeting regarding settlement.				
02/24/21	Sheila Birnbaum	0.50	L160	A107	750.00
	Telephone conference with Davis Polk regarding settlement issues.				
02/24/21	Hayden Coleman	6.30	L160	A104	6,615.00
	Review and analyze case time line through plan confirmation (0.4); review and respond to comments to Plan/personal injury issues and corresponding trust documents (2.2); review and revise memorandum regarding financial and structural deficiencies with proposed asset sales (3.7).				
02/24/21	Hayden Coleman	1.90	L160	A105	1,995.00
	Conferences and correspondence with Dechert team regarding financial and structural deficiencies with proposed asset sales (1.9).				
02/25/21	Sheila Birnbaum	0.40	L160	A106	600.00
	Telephone conference regarding preparation for mediator orientation with Purdue and Dechert.				
02/25/21	Hayden Coleman	0.30	L160	A106	315.00
	Emails with Dechert team regarding proposed confirmation timeline.				
02/26/21	Hayden Coleman	1.40	L160	A104	1,470.00
	Review Tribe trust documents and related emails with DPW regarding settlement (0.7); review and comment on Cornerstone updated analysis regarding same (0.7).				
02/28/21	Sara Roitman	1.20	L160	A104	1,260.00
	Review proposed trust agreements for the tribes and third party payors.				
L160 SUBTOTAL HOURS AND FEES:		133.50			170,520.00

L210 – Pleadings

02/01/21	Shmuel Vasser	1.50	L210	A104	1,875.00
	Review insurance complaint.				
02/01/21	Christopher Boisvert	0.20	L210	A106	195.00
	Correspond with M. Leventhal regarding McCallister Motion to Unseal.				
02/02/21	Sheila Birnbaum	1.60	L210	A104	2,400.00
	Review Judge Polster decision on Neonatal Abstinence Syndrome class action (0.8); review District Court opinion regarding Neonatal Abstinence Syndrome class action (0.8).				
02/02/21	Hayden Coleman	1.40	L210	A104	1,470.00
	Review class action filed by West Virginia municipalities against McKinsey (1.4).				
02/02/21	Hayden Coleman	0.40	L210	A107	420.00
	Emails with client, Dechert, and DPW regarding class action filed by West Virginia municipalities against McKinsey (0.4).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 32

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/02/21	Paul LaFata	0.30	L210	A104	292.50
	Analyze new complaint (WV).				
02/02/21	Shmuel Vasser	2.10	L210	A104	2,625.00
	Review pleadings regarding discovery and case status.				
02/04/21	Alyssa Clark	2.40	L210	A103	1,896.00
	Draft notice of bankruptcy and affirmation of service for Schwartz case (2.4).				
02/04/21	Christopher Boisvert	1.60	L210	A103	1,560.00
	Draft and revise notice of suggestion of bankruptcy in Schwartz pro se case.				
02/04/21	Danielle Gentin Stock	0.10	L210	A107	97.50
	Correspond with co-counsel regarding pro se complaint.				
02/05/21	Hayden Coleman	0.80	L210	A104	840.00
	Review Bloyd and Find adversary complaint and attendant emails (0.8).				
02/05/21	Paul LaFata	0.20	L210	A104	195.00
	Analyze pleadings regarding claims status.				
02/05/21	Alyssa Clark	0.50	L210	A103	395.00
	Finalize notice of bankruptcy and affirmation of service for filing in Schwartz case (0.5).				
02/05/21	Christopher Boisvert	0.40	L210	A103	390.00
	Revise Schwartz Notice of Bankruptcy for filing in New York State Court.				
02/05/21	Danielle Gentin Stock	0.10	L210	A104	97.50
	Review filing regarding pro se complaint.				
02/05/21	Jefferson Holder	0.40	L210	A111	120.00
	File (.2) and serve (.2) Notice of Suggestion of Bankruptcy.				
02/08/21	Sheila Birnbaum	0.80	L210	A104	1,200.00
	Review filing from committee on Accountability to U.S. Trustee (0.8).				
02/08/21	Hayden Coleman	0.40	L210	A107	420.00
	Emails with client, DPW, and Dechert regarding Sackler motion to seal privilege logs (0.4).				
02/08/21	Shmuel Vasser	1.70	L210	A104	2,125.00
	Review pleadings regarding discovery issues.				
02/14/21	Paul LaFata	0.40	L210	A104	390.00
	Analyze pleadings regarding protective order and document disclosures.				
02/15/21	Christopher Boisvert	1.40	L210	A107	1,365.00
	Preparation for (.6) and telephone conference (.8) with client and co-counsel regarding motion to unseal documents.				
02/16/21	Shmuel Vasser	2.70	L210	A104	3,375.00
	Review motion to extend exclusivity (1.0); review Dow Jones's reply regarding unsealing motion (1.7).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 33

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/17/21	Shmuel Vasser	1.30	L210	A104	1,625.00
	Review sealing opinion.				
02/18/21	Hayden Coleman	0.20	L210	A104	210.00
	Review Sackler motion to seal documents (0.2).				
02/18/21	Danielle Gentin Stock	0.30	L210	A104	292.50
	Review Sackler party pleading.				
02/22/21	Sheila Birnbaum	0.90	L210	A104	1,350.00
	Review Neonatal Abstinence Syndrome 2004 motion and emails regarding same (0.9).				
02/22/21	Paul LaFata	0.10	L210	A104	97.50
	Analyze proposed stipulation on automatic stay (VA).				
02/22/21	Danielle Gentin Stock	0.40	L210	A104	390.00
	Review and analyze pleadings in NY litigation (0.4).				
02/24/21	Danielle Gentin Stock	0.30	L210	A104	292.50
	Review newly filed adversary proceeding pleadings.				
02/26/21	Shmuel Vasser	1.00	L210	A104	1,250.00
	Review exclusivity extension motion.				

L210 SUBTOTAL HOURS AND FEES:	25.90	29,251.00
--------------------------------------	--------------	------------------

L220 – Preliminary Injunctions/Provisional Remedies

02/10/21	Danielle Gentin Stock	0.40	L220	A104	390.00
	Review and analyze material relevant to client's injunction query.				
02/18/21	Hayden Coleman	1.20	L220	A105	1,260.00
	Emails and conferences with Dechert team regarding ramifications of proposed sales structure on voluntary injunction (1.2).				
02/18/21	Hayden Coleman	0.80	L220	A103	840.00
	Draft memorandum regarding Insys asset sale and potential conflicts with voluntary injunction.				
02/26/21	Paul LaFata	0.10	L220	A104	97.50
	Analyze pleadings on extending preliminary injunction.				

L220 SUBTOTAL HOURS AND FEES:	2.50	2,587.50
--------------------------------------	-------------	-----------------

L230 – Court Mandated Conferences

02/04/21	Hayden Coleman	0.60	L230	A109	630.00
	Attend court conference on neonatal abstinence syndrome motion to compel production from Sacklers.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 34

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/16/21	Paul LaFata	0.10	L230	A104	97.50
	Analyze revisions to hearing agenda on privilege motions.				
02/17/21	Sheila Birnbaum	3.00	L230	A109	4,500.00
	Attend Omnibus Hearing.				
02/17/21	Hayden Coleman	3.10	L230	A109	3,255.00
	Attend Omnibus Hearing.				
02/17/21	Paul LaFata	2.40	L230	A109	2,340.00
	Attend motion argument on privilege motions.				
02/17/21	Danielle Gentin Stock	3.10	L230	A109	3,022.50
	Attend telephonic Bankruptcy Court hearing.				
L230 SUBTOTAL HOURS AND FEES:		12.30			13,845.00
L250 – Other Written Motions and Submissions					
02/17/21	Alyssa Clark	1.60	L250	A104	1,264.00
	Revise draft joint status report (0.5, NY); draft summary of decision on motion for summary judgment (1.1, NY).				
L250 SUBTOTAL HOURS AND FEES:		1.60			1,264.00
L310 – Written Discovery					
02/01/21	Danielle Gentin Stock	0.20	L310	A107	195.00
	Review correspondence regarding neonatal abstinence syndrome claimants' discovery.				
02/02/21	Hayden Coleman	0.40	L310	A108	420.00
	Emails with Dechert, DPW, and D. Wiggins regarding neonatal abstinence syndrome Ad Hoc Committee inquiries and discovery requests.				
02/02/21	Hayden Coleman	0.90	L310	A104	945.00
	Review and comment on emails from Neonatal Abstinence Syndrome groups regarding discovery requests (0.9).				
02/02/21	Danielle Gentin Stock	0.10	L310	A107	97.50
	Correspond with co-counsel regarding neonatal abstinence syndrome discovery request.				
02/04/21	Hayden Coleman	0.50	L310	A107	525.00
	Emails with DPW, Dechert, and Wiggins regarding Neonatal Abstinence Syndrome group's request for information.				
02/04/21	Danielle Gentin Stock	0.20	L310	A104	195.00
	Review correspondence regarding neonatal abstinence syndrome request for information.				
02/05/21	Hayden Coleman	0.80	L310	A108	840.00
	Emails with Dechert, DPW, and Wiggins regarding neonatal abstinence syndrome Ad Hoc Committee discovery requests (0.8).				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 35

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/08/21	Danielle Gentin Stock	0.20	L310	A104	195.00
	Review correspondence regarding neonatal abstinence syndrome discovery requests.				
02/09/21	Hayden Coleman	0.50	L310	A107	525.00
	Communicate with DPW and client regarding Neonatal Abstinence Syndrome Ad Hoc Committee discovery requests (0.5).				
02/09/21	Danielle Gentin Stock	0.30	L310	A104	292.50
	Review correspondence related to neonatal abstinence syndrome Committee discovery requests.				
02/09/21	Danielle Gentin Stock	0.80	L310	A106	780.00
	Confer with client regarding discovery issues.				
02/10/21	Hayden Coleman	1.10	L310	A107	1,155.00
	Plan for and participate in conference call with client, Dechert, and DPW teams regarding neonatal abstinence syndrome Ad Hoc Committee discovery requests.				
02/10/21	Danielle Gentin Stock	0.30	L310	A104	292.50
	Review correspondence regarding neonatal abstinence syndrome Committee discovery requests.				
02/10/21	Danielle Gentin Stock	0.80	L310	A107	780.00
	Confer with co-counsel and client regarding neonatal abstinence syndrome Committee discovery request.				
02/16/21	Danielle Gentin Stock	0.80	L310	A107	780.00
	Prepare for and confer with co-counsel regarding neonatal abstinence syndrome Committee discovery request (0.3); join meet and confer with neonatal abstinence syndrome Committee regarding discovery request (0.4); correspond with co-counsel regarding neonatal abstinence syndrome discovery request (0.1).				
02/22/21	Hayden Coleman	0.30	L310	A104	315.00
	Review emails from Neonatal Abstinence Syndrome group regarding discovery requests and discovery request for meet and confer (0.3).				
02/22/21	Danielle Gentin Stock	0.20	L310	A107	195.00
	Correspond with co-counsel regarding neonatal abstinence syndrome Committee discovery request.				
02/22/21	Danielle Gentin Stock	0.20	L310	A104	195.00
	Review correspondence regarding neonatal abstinence syndrome Committee discovery.				
02/22/21	Danielle Gentin Stock	0.20	L310	A105	195.00
	Confer internally regarding neonatal abstinence syndrome Committee discovery request.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 36

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/23/21	Danielle Gentin Stock	0.40	L310	A107	390.00
	Confer with co-counsel regarding neonatal abstinence syndrome Committee discovery request.				
02/23/21	Danielle Gentin Stock	0.60	L310	A105	585.00
	Correspond internally regarding neonatal abstinence syndrome discovery issues.				
02/24/21	Danielle Gentin Stock	0.20	L310	A107	195.00
	Correspond with co-counsel regarding neonatal abstinence syndrome issues.				
02/25/21	Danielle Gentin Stock	0.90	L310	A107	877.50
	Confer with neonatal abstinence syndrome Committee in meet and confer regarding discovery requests (0.5); correspond and review correspondence with co-counsel regarding same (0.4).				
02/26/21	Hayden Coleman	1.50	L310	A107	1,575.00
	Emails and conference calls with DPW and Wiggins regarding response to Neonatal Abstinence Syndrome group discovery requests for documents (1.5).				
02/26/21	Danielle Gentin Stock	0.20	L310	A107	195.00
	Confer with co-counsel regarding neonatal abstinence syndrome discovery response.				
02/26/21	Danielle Gentin Stock	0.30	L310	A104	292.50
	Review and revise response to neonatal abstinence syndrome discovery request.				
02/26/21	Danielle Gentin Stock	0.30	L310	A105	292.50
	Confer internally regarding neonatal abstinence syndrome discovery request.				
L310 SUBTOTAL HOURS AND FEES:		13.20			13,320.00
L320 – Document Production					
02/01/21	Michelle Yeary	2.50	L320	A104	2,437.50
	Review confidential materials for McCallister matter.				
02/02/21	Michelle Yeary	2.60	L320	A104	2,535.00
	Respond to email from H. Coleman regarding status of confidentiality review in McCallister (.4), continue review of confidential McCallister documents (2.0), review email from media intervenors regarding request for video data (.2).				
02/03/21	Michelle Yeary	2.60	L320	A104	2,535.00
	Review documents subject to potential unsealing in McCallister.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 37

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/04/21	Michelle Yeary	3.90	L320	A104	3,802.50
	Review sealed McCallister dockets (.5); prepare notes on remaining confidentiality concerns (1.5); telephone conference with Dechert team and local counsel on next steps in McCallister motion to unseal (.5); continue investigation into documents produced in McCallister versus documents filed with the court (1.4).				
02/04/21	Antonella Capobianco-Ranallo	3.10	L320	A104	930.00
	Review documents filed under seal in McCallister v. Purdue (2.1); prepare index regarding same (1.1).				
02/04/21	Antonella Capobianco-Ranallo	0.30	L320	A105	90.00
	Email with M. Yeary regarding documents filed under seal in McCallister v. Purdue and related index (.3).				
02/05/21	Michelle Yeary	2.60	L320	A102	2,535.00
	Continue research and analysis of documents filed under seal in McCallister.				
02/10/21	Michelle Yeary	2.50	L320	A104	2,437.50
	Review sealed portions of McCallister deposition exhibits for confidentiality.				
02/11/21	Michelle Yeary	1.00	L320	A104	975.00
	Review McCallister deposition exhibits for confidentiality.				
02/12/21	Christopher Boisvert	0.40	L320	A104	390.00
	Review redactions in outstanding exhibits subject to media's motion to unseal documents.				
02/15/21	Hayden Coleman	1.20	L320	A106	1,260.00
	Plan for and participate in WebEx with client regarding contested redactions and preparation for omnibus hearing.				
02/22/21	Mara Cusker Gonzalez	0.50	L320	A108	525.00
	Confer with counsel for co-defendant manufacturer regarding Purdue document confidentiality designations.				
02/22/21	Paul LaFata	0.20	L320	A106	195.00
	Confer with client and co-defense counsel regarding document production strategy.				
02/25/21	Michelle Yeary	0.20	L320	A104	195.00
	Review order in McCallister regarding motion to intervene for document review.				
L320 SUBTOTAL HOURS AND FEES:		23.60			20,842.50

L440 – Other Trial Preparation and Support

02/01/21	Nicholas Dean	1.50	L440	A104	697.50
	Analyze proposed documents for pre-trial stipulation in WV.				
02/08/21	Nicholas Dean	2.50	L440	A104	1,162.50
	Analyze proposed documents for pre-trial stipulation in WV.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 38

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/09/21	Nicholas Dean	4.00	L440	A104	1,860.00
	Analyze proposed documents for pre-trial stipulation in WV.				
02/10/21	Paul LaFata	0.20	L440	A104	195.00
	Analyze correspondence regarding trial stipulation.				
02/10/21	Nicholas Dean	5.20	L440	A104	2,418.00
	Analyze proposed documents for pre-trial stipulation in WV.				
02/16/21	Nicholas Dean	0.50	L440	A104	232.50
	Analyze proposed documents for pre-trial stipulation in WV.				
02/22/21	Paul LaFata	0.40	L440	A104	390.00
	Analyze demand for trial stipulation.				
02/22/21	Paul LaFata	0.30	L440	A107	292.50
	Confer with co-counsel regarding demand for trial stipulation.				
02/22/21	Paul LaFata	0.10	L440	A106	97.50
	Confer with client regarding demand for trial stipulation.				
02/22/21	Nicholas Dean	0.90	L440	A104	418.50
	Analyze proposed documents for pre-trial stipulation in WV.				
02/23/21	Paul LaFata	0.30	L440	A106	292.50
	Confer with client regarding trial stipulation demand.				
02/23/21	Paul LaFata	0.50	L440	A108	487.50
	Confer with plaintiffs regarding response to trial stipulation demand.				
02/23/21	Paul LaFata	0.40	L440	A107	390.00
	Confer with counsel regarding trial stipulation demand.				
02/23/21	Paul LaFata	1.00	L440	A104	975.00
	Analyze documents in support of trial stipulation.				
02/23/21	Paul LaFata	1.40	L440	A103	1,365.00
	Revise documents in support of trial stipulation.				
02/23/21	Nicholas Dean	2.10	L440	A104	976.50
	Analyze proposed documents for pre-trial stipulation in WV.				
02/23/21	Antonella Capobianco-Ranallo	4.30	L440	A104	1,290.00
	Review documents regarding trial stipulation project (4.3).				
02/23/21	Antonella Capobianco-Ranallo	0.20	L440	A105	60.00
	Email with P. LaFata regarding trial stipulation project (.2).				
02/24/21	Paul LaFata	1.70	L440	A104	1,657.50
	Analyze documents for trial stipulation.				
02/24/21	Paul LaFata	0.20	L440	A106	195.00
	Confer with client regarding trial stipulation.				
02/24/21	Paul LaFata	0.50	L440	A107	487.50
	Confer with co-counsel regarding trial stipulation.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 39

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/24/21	Paul LaFata	0.10	L440	A108	97.50
	Confer with plaintiffs regarding trial stipulation.				
02/24/21	Nicholas Dean	2.10	L440	A104	976.50
	Analyze proposed documents for pre-trial stipulation in WV.				
02/24/21	Antonella Capobianco-Ranallo	1.00	L440	A104	300.00
	Review documents regarding trial stipulation project.				
02/25/21	Paul LaFata	0.40	L440	A107	390.00
	Confer with counsel regarding analysis of documents for trial stipulation.				
02/25/21	Paul LaFata	2.20	L440	A104	2,145.00
	Analyze documents for trial stipulation.				
02/25/21	Nicholas Dean	3.90	L440	A104	1,813.50
	Analyze proposed documents for pre-trial stipulation in W.VA.				
02/25/21	Antonella Capobianco-Ranallo	1.70	L440	A104	510.00
	Review documents regarding trial stipulation project.				
02/26/21	Paul LaFata	0.90	L440	A106	877.50
	Confer with client regarding document analysis and trial stipulation.				
02/26/21	Paul LaFata	0.60	L440	A107	585.00
	Confer with co-counsel regarding document analysis and trial stipulation.				
02/26/21	Paul LaFata	2.00	L440	A104	1,950.00
	Review documents for trial stipulation.				
02/26/21	Nicholas Dean	0.90	L440	A104	418.50
	Analyze proposed documents for pre-trial stipulation in WV.				
02/26/21	Antonella Capobianco-Ranallo	3.20	L440	A104	960.00
	Prepare documents regarding trial stipulation project.				
02/28/21	Paul LaFata	0.20	L440	A107	195.00
	Confer with co-counsel regarding trial stipulation.				
02/28/21	Paul LaFata	1.00	L440	A104	975.00
	Analyze documents for trial stipulation.				
02/28/21	Nicholas Dean	2.50	L440	A104	1,162.50
	Analyze proposed documents for pre-trial stipulation in WV.				
L440 SUBTOTAL HOURS AND FEES:		50.90			29,296.50
TOTAL HOURS AND FEES		599.10			USD 626,789.50

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 40

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>TIMEKEEPER SUMMARY:</u>				
<u>TIMEKEEPER</u>	<u>TITLE</u>	<u>RATE</u>	<u>HOURS</u>	<u>AMOUNT</u>
S. Birnbaum	Partner	1,500.00	103.80	155,700.00
S. Vasser	Partner	1,250.00	18.90	23,625.00
H. Coleman	Partner	1,050.00	153.40	161,070.00
M. Cusker Gonzalez	Partner	1,050.00	14.10	14,805.00
S. Roitman	Partner	1,050.00	61.80	64,890.00
P. LaFata	Partner	975.00	20.60	20,085.00
J. Tam	Partner	975.00	3.20	3,120.00
J. Newmark	Associate	950.00	41.20	39,140.00
M. Kim	Associate	880.00	0.30	264.00
L. Zanello	Associate	880.00	0.60	528.00
A. Clark	Associate	790.00	4.50	3,555.00
R. Gledhill	Associate	790.00	2.40	1,896.00
T. Yale	Associate	790.00	10.40	8,216.00
N. Becker	Associate	630.00	16.80	10,584.00
N. Dean	Staff Attorney	465.00	26.10	12,136.50
C. Boisvert	Counsel	975.00	5.00	4,875.00
D. Gentin Stock	Counsel	975.00	82.10	80,047.50
M. Yeary	Counsel	975.00	17.90	17,452.50
A. Capobianco-Ranallo	Legal Assistant	300.00	15.20	4,560.00
J. Holder	Legal Assistant	300.00	0.40	120.00
M. Stone	Legal Assistant	300.00	0.40	120.00
TOTALS			599.10	USD 626,789.50



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P.
201 Tresser Blvd.
Stamford, CT 06901

April 30, 2021
Invoice Number
1010012656

Firm Client Matter Number: 399631.178405

Client Name: Purdue Pharma L.P.
Matter Name: Mediation & Settlement, Claims Evaluation, and Operations
Electronic Billing Number: 20210003064

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICE USD 534,129.60

REMITTANCE INSTRUCTIONS
For questions about payment instruction please call (215) 994-4000
Payment by Wire or ACH
Bank Name: Citi Private Bank Bank Address: 153 East 53rd St., New York, NY Account Name: Dechert LLP Main Account Account #: 759527772 ABA #: 021272655 Swift Code: CITIUS33
Payment by Check (U.S. Only)
Please include this remittance or print the invoice number (1010012656) in the check memo. Mail to: Dechert LLP P.O. Box 7247-6643 Philadelphia, PA 19170-6643



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

Purdue Pharma L.P.
201 Tresser Blvd.
Stamford, CT 06901

April 30, 2021
Invoice Number 1010012657

Firm Client Matter Number: 399631.178406

Client Name: Purdue Pharma L.P.
Matter Name: Fee Applications and Related Expenses
Electronic Billing Number: 20190002705

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL FEES FOR THIS INVOICE.....46,265.50

Less 15% Discount(6,939.83)

NET TOTAL FEES FOR THIS INVOICE 39,325.67

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 39,325.67

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178406

Invoice 1010012657
Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
B160 – Fee/Employment Applications					
02/01/21	Hayden Coleman	0.20	B160	A105	210.00
	Emails with Dechert team regarding November invoices.				
02/01/21	Hayden Coleman	1.90	B160	A104	1,995.00
	Review and revise November invoices.				
02/01/21	Shmuel Vasser	0.50	B160	A103	625.00
	Review November fee statement.				
02/01/21	Katherine Norman	0.50	B160	A105	315.00
	Review emails from H. Coleman, S. Vasser, and B. Stone regarding Purdue fee statements (.3); review emails from S. Vasser, B. Stone, and I. Campos regarding notice of IP rate increases (.2).				
02/01/21	Matthew Stone	1.60	B160	A103	480.00
	Prepare (1.2), file (.2), and serve (.2) notice of increase regarding IP fees.				
02/01/21	Matthew Stone	3.40	B160	A103	1,020.00
	Review and edit December fee statement (3.4).				
02/01/21	Matthew Stone	0.50	B160	A105	150.00
	Email with attorneys regarding December invoices (.5).				
02/01/21	Matthew Stone	0.20	B160	A105	60.00
	Email with S. Vasser regarding notice of increase regarding IP fees.				
02/02/21	Katherine Norman	0.10	B160	A105	63.00
	Email correspondence with B. Stone regarding December fee statements (.1).				
02/02/21	Matthew Stone	0.30	B160	A105	90.00
	Email with C. Norman regarding December invoices (.3).				
02/02/21	Matthew Stone	1.80	B160	A103	540.00
	Review and edit December fee statement (1.6).				
02/03/21	Hayden Coleman	0.40	B160	A105	420.00
	Email with B. Stone regarding December 2020 bills.				
02/03/21	Shmuel Vasser	0.50	B160	A105	625.00
	Emails with Dechert team regarding time entries.				
02/03/21	Katherine Norman	0.20	B160	A105	126.00
	Email correspondence with B. Stone regarding December fee statement (.2).				
02/03/21	Katherine Norman	1.90	B160	A103	1,197.00
	Review and revise December fee statement invoice.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178406

Invoice 1010012657
Page 3

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/03/21	Matthew Stone	4.50	B160	A103	1,350.00
	Revise invoices for December fee statement (3.9); draft fee statements for December (.3) and January (.3).				
02/03/21	Matthew Stone	0.70	B160	A105	210.00
	Email correspondence with H. Coleman and S. Vasser regarding December invoices.				
02/04/21	Katherine Norman	0.50	B160	A105	315.00
	Call with B. Stone regarding fee statements and interim fee application (.5).				
02/05/21	Matthew Stone	3.80	B160	A103	1,140.00
	Revise invoices for January fee statement (3.1); finalize invoices for November fee statement (0.7).				
02/08/21	Shmuel Vasser	1.60	B160	A104	2,000.00
	Review November time records.				
02/08/21	Matthew Stone	2.00	B160	A103	600.00
	Revise invoices for January fee statement (2.0).				
02/08/21	Matthew Stone	0.30	B160	A105	90.00
	Email correspondence with Dechert team regarding January invoices.				
02/09/21	Katherine Norman	0.60	B160	A103	378.00
	Revise December fee statement (.6).				
02/09/21	Matthew Stone	2.80	B160	A103	840.00
	Revise invoices for January fee statement (2.8).				
02/09/21	Matthew Stone	0.30	B160	A105	90.00
	Email correspondence with Dechert team regarding January invoices.				
02/10/21	Katherine Norman	2.30	B160	A103	1,449.00
	Revise December invoice for fee statement (2.3).				
02/10/21	Matthew Stone	0.60	B160	A105	180.00
	Email with Dechert team regarding January invoices (.4); email with S. Vasser regarding November fee statement (.2).				
02/10/21	Matthew Stone	5.50	B160	A103	1,650.00
	Review and edit January fee statement (2.4); prepare November fee statement (3.1).				
02/11/21	Shmuel Vasser	1.60	B160	A103	2,000.00
	Review and revise draft November fee statement.				
02/11/21	Matthew Stone	2.00	B160	A103	600.00
	Revise (.8), file (.2), and serve (.2) November fee statement; review and edit December fee statement (.8).				
02/11/21	Matthew Stone	0.20	B160	A105	60.00
	Email with S. Vasser regarding November fee statement.				
02/12/21	Shmuel Vasser	2.50	B160	A104	3,125.00
	Review December time entries for municipalities matter.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178406

Invoice 1010012657
Page 4

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/12/21	Matthew Stone	3.40	B160	A103	1,020.00
	Review and edit invoices for December (1.2) and January (2.2) fee statement.				
02/17/21	Shmuel Vasser	0.50	B160	A103	625.00
	Revise December fee statement.				
02/17/21	Matthew Stone	1.80	B160	A103	540.00
	Review and edit invoices regarding January fee statement.				
02/17/21	Matthew Stone	0.20	B160	A108	60.00
	Email with fee examiner regarding November fee statement.				
02/17/21	Matthew Stone	0.30	B160	A105	90.00
	Email with H. Coleman regarding December invoices.				
02/18/21	Hayden Coleman	1.30	B160	A104	1,365.00
	Review December fee statement.				
02/18/21	Matthew Stone	3.40	B160	A103	1,020.00
	Revise December fee statement (3.4).				
02/18/21	Matthew Stone	0.20	B160	A105	60.00
	Email with H. Coleman regarding December invoices (.2).				
02/19/21	Shmuel Vasser	1.40	B160	A104	1,750.00
	Review December IP time entries (1.4).				
02/19/21	Shmuel Vasser	0.20	B160	A105	250.00
	Email with B. Stone regarding December IP time entries (.2).				
02/19/21	Matthew Stone	0.20	B160	A108	60.00
	Email with Fee Examiner regarding November fee statement.				
02/19/21	Matthew Stone	2.10	B160	A103	630.00
	Revise invoices for December fee statement.				
02/19/21	Matthew Stone	0.40	B160	A105	120.00
	Email with H. Coleman (.2) and S. Vasser (.2) regarding December fee statement.				
02/22/21	Matthew Stone	4.20	B160	A103	1,260.00
	Revise invoices for January fee statement.				
02/23/21	Matthew Stone	2.70	B160	A103	810.00
	Prepare December fee statement and exhibits (2.3); file (.2) and serve (.2) same.				
02/23/21	Matthew Stone	0.30	B160	A105	90.00
	Email with S. Vasser regarding December fee statement (.2); email with Dechert team regarding objection deadline for same (.1).				
02/24/21	Matthew Stone	4.70	B160	A103	1,410.00
	Review and edit invoices for January fee statement.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178406

Invoice 1010012657
Page 5

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/25/21	Hayden Coleman	0.30	B160	A105	315.00
	Email correspondence with Dechert team regarding vendor invoices (0.3).				
02/25/21	Matthew Stone	0.90	B160	A105	270.00
	Email with attorneys regarding January fee statement (.8); email with billing department regarding December fee statement (.1).				
02/25/21	Matthew Stone	4.80	B160	A103	1,440.00
	Review and edit invoices for January fee statement.				
02/26/21	Matthew Stone	1.40	B160	A103	420.00
	Review and edit invoices for January fee statement.				
02/26/21	Matthew Stone	0.50	B160	A105	150.00
	Email with S. Roitman regarding interim fee application.				
B160 SUBTOTAL HOURS AND FEES:		81.00			37,748.00

B165 – Budgeting (case)

02/01/21	Shmuel Vasser	1.50	B165	A103	1,875.00
	Review revised rates for IP work (0.8); review notice regarding same (0.7).				
02/23/21	Hayden Coleman	0.50	B165	A106	525.00
	Conference call with client regarding budgets and related issues.				
02/24/21	Shmuel Vasser	1.00	B165	A105	1,250.00
	Email internally regarding budget issues.				
02/24/21	Danielle Gentin Stock	0.20	B165	A105	195.00
	Confer internally regarding budgets.				
02/24/21	Danielle Gentin Stock	0.30	B165	A106	292.50
	Confer with client regarding budgets.				
02/24/21	Matthew Stone	0.20	B165	A105	60.00
	Email with S. Vasser regarding budget preparation.				
02/24/21	Matthew Stone	0.80	B165	A103	240.00
	Review materials regarding budget preparation.				
02/25/21	Hayden Coleman	0.30	B165	A106	315.00
	Emails with client regarding budgets.				
02/25/21	Hayden Coleman	0.50	B165	A105	525.00
	Conference call with S. Vasser and D. Gentin Stock regarding budgets.				
02/25/21	Danielle Gentin Stock	1.00	B165	A105	975.00
	Confer internally regarding budgeting (0.8); correspond internally regarding budgeting (0.2).				
02/25/21	Danielle Gentin Stock	0.30	B165	A106	292.50
	Correspond with client regarding budgeting.				
02/25/21	Matthew Stone	0.40	B165	A103	120.00
	Prepare quarterly budgets.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178406

Invoice 1010012657
Page 6

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/25/21	Matthew Stone	0.60	B165	A105	180.00
	Email with H. Coleman (.3) and D. Gentin-Stock (.3) regarding budget preparation.				
02/26/21	Hayden Coleman	0.40	B165	A105	420.00
	Conference call with Dechert team regarding budget.				
02/26/21	Jonathan Tam	0.50	B165	A105	487.50
	Confer in firm regarding case budget.				
02/26/21	Danielle Gentin Stock	0.60	B165	A105	585.00
	Confer and correspond internally regarding Purdue budget.				
02/26/21	Matthew Stone	0.20	B165	A105	60.00
	Email with D. Gentin-Stock regarding budget preparation.				
02/26/21	Matthew Stone	0.40	B165	A103	120.00
	Prepare summary regarding quarterly budgets.				
B165 SUBTOTAL HOURS AND FEES:		9.70			8,517.50
TOTAL HOURS AND FEES		90.70			USD 46,265.50

TIMEKEEPER SUMMARY:

<u>TIMEKEEPER</u>	<u>TITLE</u>	<u>RATE</u>	<u>HOURS</u>	<u>AMOUNT</u>
S. Vasser	Partner	1,250.00	11.30	14,125.00
H. Coleman	Partner	1,050.00	5.80	6,090.00
J. Tam	Partner	975.00	0.50	487.50
K. Norman	Associate	630.00	6.10	3,843.00
D. Gentin Stock	Counsel	975.00	2.40	2,340.00
M. Stone	Legal Assistant	300.00	64.60	19,380.00
TOTALS			90.70	USD 46,265.50



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P.
201 Tresser Blvd.
Stamford, CT 06901

April 30, 2021
Invoice Number
1010012657

Firm Client Matter Number: 399631.178406

Client Name: Purdue Pharma L.P.
Matter Name: Fee Applications and Related Expenses
Electronic Billing Number: 20190002705

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 39,325.67

REMITTANCE INSTRUCTIONS
For questions about payment instruction please call (215) 994-4000
Payment by Wire or ACH
Bank Name: Citi Private Bank Bank Address: 153 East 53rd St., New York, NY Account Name: Dechert LLP Main Account Account #: 759527772 ABA #: 021272655 Swift Code: CITIUS33
Payment by Check (U.S. Only)
Please include this remittance or print the invoice number (1010012657) in the check memo. Mail to: Dechert LLP P.O. Box 7247-6643 Philadelphia, PA 19170-6643



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

Purdue Pharma L.P.
One Stamford Forum
Stamford, CT 06901

April 30, 2021
Invoice Number 1010012650

Firm Client Matter Number: 379612.156278

Client Name: Purdue Pharma L.P.
Matter Name: (477C1) (13-MP-0017US03) Reduction of Alpha, Beta-Unsaturated Ketone Levels in Morphinan
Derivative
Electronic Billing Number: 20170001301

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL FEES FOR THIS INVOICE.....9,192.00

Less 8% Discount(735.36)

NET TOTAL FEES FOR THIS INVOICE 8,456.64

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 8,456.64

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P.
Firm Matter Number: 379612.156278

Invoice 1010012650
Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
P260 – Intellectual Property					
02/01/21	Blaine Hackman	1.00	P260	A104	765.00
	Analyze Patent Trial and Appeal Board case law to rebut examiner's rejection arguments.				
02/02/21	Blaine Hackman	4.50	P260	A104	3,442.50
	Continue to analyze Patent Trial and Appeal Board case law to rebut examiner's rejection arguments (2.3); prepare a summary of the case law findings (0.9); prepare strategy to respond, and possibly appeal, the outstanding final office action (1.3).				
02/03/21	Blaine Hackman	3.00	P260	A101	2,295.00
	Prepare arguments and a strategy to respond, and possibly appeal, the outstanding final office action from the USPTO.				
02/17/21	Samuel Abrams	0.80	P260	A103	744.00
	Revise response to Office Action (.8).				
02/17/21	Samuel Abrams	0.20	P260	A105	186.00
	Email with Dr. Hackman regarding response to Office Action (.2).				
02/18/21	Blaine Hackman	0.30	P260	A106	229.50
	Prepare draft correspondence with W. Yang regarding Final Office Action.				
02/18/21	Blaine Hackman	0.30	P260	A105	229.50
	Conference with S. Abrams regarding the response strategy for the Final Office Action.				
02/19/21	Blaine Hackman	1.30	P260	A104	994.50
	Prepare analysis of the Final Office Action and proposed response strategy.				
02/19/21	Blaine Hackman	0.40	P260	A105	306.00
	Correspond with S. Abrams regarding the analysis of the Final Office Action and proposed response strategy.				
P260 SUBTOTAL HOURS AND FEES:		11.80			9,192.00
TOTAL HOURS AND FEES		11.80			USD 9,192.00

Client Name: Purdue Pharma L.P.
Firm Matter Number: 379612.156278

Invoice 1010012650
Page 3

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>TIMEKEEPER SUMMARY:</u>				
<u>TIMEKEEPER</u>	<u>TITLE</u>	<u>RATE</u>	<u>HOURS</u>	<u>AMOUNT</u>
S. Abrams	Partner	930.00	1.00	930.00
B. Hackman	Associate	765.00	10.80	8,262.00
TOTALS			11.80	USD 9,192.00

DISBURSEMENTS:

<u>DESCRIPTION</u>	<u>AMOUNT</u>
Westlaw Search Fees	
Westlaw Search Fees	0.00
	0.00
TOTAL DISBURSEMENTS	USD 0.00



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P.
One Stamford Forum
Stamford, CT 06901

April 30, 2021
Invoice Number
1010012650

Firm Client Matter Number: 379612.156278

Client Name: Purdue Pharma L.P.
Matter Name: (477C1) (13-MP-0017US03) Reduction of Alpha, Beta-Unsaturated Ketone Levels in Morphinan
Derivative
Electronic Billing Number: 20170001301

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 8,456.64

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010012650) in the check memo. Mail to:
Dechert LLP | P.O. Box 7247-6643 Philadelphia, PA | 19170-6643



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

Purdue Pharma L.P.
One Stamford Forum
Stamford, CT 06901

April 30, 2021
Invoice Number 1010012651

Firm Client Matter Number: 379612.168206

Client Name: Purdue Pharma L.P.
Matter Name: (478D2C1) (14-PS-0018US07) Acetate Salt of Buprenorphine and Methods for Preparing
Buprenorphine
Electronic Billing Number: 20190002532

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL FEES FOR THIS INVOICE	2,206.50
Less 8% Discount	(176.52)
NET TOTAL FEES FOR THIS INVOICE.....	2,029.98
TOTAL DISBURSEMENTS THIS INVOICE	14.92
TOTAL AMOUNT DUE FOR THIS INVOICE	USD 2,044.90

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P.
Firm Matter Number: 379612.168206

Invoice 1010012651
Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
P260 – Intellectual Property					
02/02/21	Blaine Hackman	1.80	P260	A104	1,377.00
	Analyze the issued claims to provide a summary of current claim coverage.				
02/03/21	Blaine Hackman	0.60	P260	A106	459.00
	Prepare correspondence to W. Yang regarding patent family coverage.				
02/24/21	Sherrice Breland	0.60	P260	A104	171.00
	Review file (0.1); review Notice of Publication (0.1); review U.S. Publication (0.1); review and organize correspondence and prosecution history (0.3).				
02/24/21	Sherrice Breland	0.20	P260	A105	57.00
	Confer with B. Hackman regarding Notice of Publication (0.2).				
02/24/21	Sherrice Breland	0.50	P260	A106	142.50
	Draft and revise letter to client regarding Notice of Publication (0.5).				
P260 SUBTOTAL HOURS AND FEES:		3.70			2,206.50
TOTAL HOURS AND FEES		3.70			USD 2,206.50

TIMEKEEPER SUMMARY:

<u>TIMEKEEPER</u>	<u>TITLE</u>	<u>RATE</u>	<u>HOURS</u>	<u>AMOUNT</u>
B. Hackman	Associate	765.00	2.40	1,836.00
S. Breland	Legal Assistant	285.00	1.30	370.50
TOTALS			3.70	USD 2,206.50



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P.
One Stamford Forum
Stamford, CT 06901

April 30, 2021
Invoice Number
1010012651

Firm Client Matter Number: 379612.168206

Client Name: Purdue Pharma L.P.
Matter Name: (478D2C1) (14-PS-0018US07) Acetate Salt of Buprenorphine and Methods for Preparing
Buprenorphine
Electronic Billing Number: 20190002532

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 2,044.90

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010012651) in the check memo. Mail to:
Dechert LLP | P.O. Box 7247-6643 Philadelphia, PA | 19170-6643



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

Purdue Pharma L.P.
One Stamford Forum
Stamford, CT 06901

April 30, 2021
Invoice Number 1010012652

Firm Client Matter Number: 379612.177870

Client Name: Purdue Pharma L.P.
Matter Name: (505USP1) (19-MT-0001US01) Overactive Bladder - ORL 1 Inhibitors for OAC
Electronic Billing Number: 20200003037

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL FEES FOR THIS INVOICE 1,480.50
Less 8% Discount (118.44)
NET TOTAL FEES FOR THIS INVOICE..... 1,362.06
TOTAL DISBURSEMENTS THIS INVOICE 99.00

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 1,461.06

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P.
Firm Matter Number: 379612.177870

Invoice 1010012652
Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
P260 – Intellectual Property					
02/09/21	Blaine Hackman	0.70	P260	A104	535.50
	Review comments from G. Whiteside regarding draft patent claims.				
02/16/21	Seth Snyder	1.10	P260	A104	693.00
	Review and analyze comments from inventor in preparation for call (.3); review follow-up questions (.3); review pharmacokinetic analysis (.5).				
02/17/21	Seth Snyder	0.40	P260	A108	252.00
	Plan for and participate in call with inventor.				
P260 SUBTOTAL HOURS AND FEES:		2.20			1,480.50
TOTAL HOURS AND FEES		2.20			USD 1,480.50

TIMEKEEPER SUMMARY:

<u>TIMEKEEPER</u>	<u>TITLE</u>	<u>RATE</u>	<u>HOURS</u>	<u>AMOUNT</u>
B. Hackman	Associate	765.00	0.70	535.50
S. Snyder	Patent Agent	630.00	1.50	945.00
TOTALS			2.20	USD 1,480.50



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P.
One Stamford Forum
Stamford, CT 06901

April 30, 2021
Invoice Number
1010012652

Firm Client Matter Number: 379612.177870

Client Name: Purdue Pharma L.P.
Matter Name: (505USP1) (19-MT-0001US01) Overactive Bladder - ORL 1 Inhibitors for OAC
Electronic Billing Number: 20200003037

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 1,461.06

REMITTANCE INSTRUCTIONS
For questions about payment instruction please call (215) 994-4000
Payment by Wire or ACH
Bank Name: Citi Private Bank Bank Address: 153 East 53rd St., New York, NY Account Name: Dechert LLP Main Account Account #: 759527772 ABA #: 021272655 Swift Code: CITIUS33
Payment by Check (U.S. Only)
Please include this remittance or print the invoice number (1010012652) in the check memo. Mail to: Dechert LLP P.O. Box 7247-6643 Philadelphia, PA 19170-6643



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

Purdue Pharma L.P.
One Stamford Forum
Stamford, CT 06901

April 30, 2021
Invoice Number 1010012653

Firm Client Matter Number: 379612.177871

Client Name: Purdue Pharma L.P.
Matter Name: (506USP1) (20-MT-0001US01) Method of Treatment Using V117957 for Treating Interstitial Cystitis
Electronic Billing Number: 20200003038

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL FEES FOR THIS INVOICE.....882.00

Less 8% Discount(70.56)

NET TOTAL FEES FOR THIS INVOICE 811.44

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 811.44

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P.
Firm Matter Number: 379612.177871

Invoice 1010012653
Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
P260 – Intellectual Property					
02/16/21	Seth Snyder	1.00	P260	A101	630.00
	Prepare follow-up questions from review of comments in preparation for call with inventor.				
02/17/21	Seth Snyder	0.40	P260	A108	252.00
	Participate in call with inventor.				
P260 SUBTOTAL HOURS AND FEES:		1.40			882.00
TOTAL HOURS AND FEES		1.40			USD 882.00

TIMEKEEPER SUMMARY:

<u>TIMEKEEPER</u>	<u>TITLE</u>	<u>RATE</u>	<u>HOURS</u>	<u>AMOUNT</u>
S. Snyder	Patent Agent	630.00	1.40	882.00
TOTALS			1.40	USD 882.00



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P.
One Stamford Forum
Stamford, CT 06901

April 30, 2021
Invoice Number
1010012653

Firm Client Matter Number: 379612.177871

Client Name: Purdue Pharma L.P.
Matter Name: (506USP1) (20-MT-0001US01) Method of Treatment Using V117957 for Treating Interstitial Cystitis
Electronic Billing Number: 20200003038

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 811.44

REMITTANCE INSTRUCTIONS
For questions about payment instruction please call (215) 994-4000
Payment by Wire or ACH
Bank Name: Citi Private Bank Bank Address: 153 East 53rd St., New York, NY Account Name: Dechert LLP Main Account Account #: 759527772 ABA #: 021272655 Swift Code: CITIUS33
Payment by Check (U.S. Only)
Please include this remittance or print the invoice number (1010012653) in the check memo. Mail to: Dechert LLP P.O. Box 7247-6643 Philadelphia, PA 19170-6643



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

Purdue Pharma L.P.
201 Tresser Blvd.
Stamford, CT 06901

April 30, 2021
Invoice Number 1010012654

Firm Client Matter Number: 399630.163596

Client Name: Purdue Pharma L.P.
Matter Name: COSTS ONLY - Joint Defense Group Expense Billing Matter
Electronic Billing Number: 20180002029 or 20180002094

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL DISBURSEMENTS THIS INVOICE201.69

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 201.69

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P.
201 Tresser Blvd.
Stamford, CT 06901

April 30, 2021
Invoice Number
1010012654

Firm Client Matter Number: 399630.163596

Client Name: Purdue Pharma L.P.
Matter Name: COSTS ONLY - Joint Defense Group Expense Billing Matter
Electronic Billing Number: 20180002029 or 20180002094

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 201.69

REMITTANCE INSTRUCTIONS
For questions about payment instruction please call (215) 994-4000
Payment by Wire or ACH
Bank Name: Citi Private Bank Bank Address: 153 East 53rd St., New York, NY Account Name: Dechert LLP Main Account Account #: 759527772 ABA #: 021272655 Swift Code: CITIUS33
Payment by Check (U.S. Only)
Please include this remittance or print the invoice number (1010012654) in the check memo. Mail to: Dechert LLP P.O. Box 7247-6643 Philadelphia, PA 19170-6643



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

Purdue Pharma L.P.
201 Tresser Blvd.
Stamford, CT 06901

April 30, 2021
Invoice Number 1010012655

Firm Client Matter Number: 399631.161942

Client Name: Purdue Pharma L.P.
Matter Name: Municipality Suits
Electronic Billing Number: 20170001582

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL FEES FOR THIS INVOICE.....17,893.50

Less 15% Discount(2,684.03)

NET TOTAL FEES FOR THIS INVOICE 15,209.47

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 15,209.47

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.161942

Invoice 1010012655
Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

PROFESSIONAL SERVICES RENDERED:

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
B110 – Case Administration					
02/01/21	Amisha Patel	0.10	B110	A105	95.00
	Correspondence with H. Coleman regarding bankruptcy stay status (0.1, DC).				
B110 SUBTOTAL HOURS AND FEES:		0.10			95.00
L120 – Analysis/Strategy					
02/01/21	Hayden Coleman	0.60	L120	A108	630.00
	Conference call and emails with outside counsel regarding West Virginia unsealing proceedings and related follow up.				
02/01/21	Hayden Coleman	0.40	L120	A105	420.00
	Email correspondence with A. Patel regarding request for status update from DC court.				
02/02/21	Hayden Coleman	0.50	L120	A107	525.00
	Conferences and emails with local counsel and Dechert regarding activity in McCallister case.				
02/02/21	Lindsay Zanello	0.10	L120	A105	88.00
	Communicate internally regarding strategy for West Virginia case.				
02/03/21	Jonathan Tam	0.40	L120	A104	390.00
	Review/analyze court decision regarding public nuisance (0.4).				
02/03/21	Mary Kim	0.60	L120	A103	528.00
	Review and draft summary of South Dakota motion to dismiss order.				
02/04/21	Hayden Coleman	0.60	L120	A105	630.00
	Conference calls with Dechert team and local WV counsel regarding McCallister.				
02/04/21	Mara Cusker Gonzalez	0.60	L120	A107	630.00
	Attend call with local WV counsel and litigation team regarding media intervenors' motion to unseal the file in McCallister.				
02/04/21	Sara Roitman	0.50	L120	A107	525.00
	Confer with local counsel and Dechert team regarding strategy for McCallister motion to intervene.				
02/04/21	Christopher Boisvert	0.50	L120	A105	487.50
	Telephone conference with Dechert team regarding current status of McCallister case and next steps.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.161942

Invoice 1010012655
Page 3

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/05/21	Lindsay Zanello	0.10	L120	A105	88.00
	Communicate internally regarding email from Discovery Commissioner in West Virginia case (.1).				
02/08/21	Mara Cusker Gonzalez	0.30	L120	A107	315.00
	Confer with litigation counsel and local counsel in McCallister (WV) regarding review of court file in connection with intervenors' motion to unseal the court record.				
02/12/21	Amisha Patel	0.10	L120	A104	95.00
	Review and analyze court order rescheduling initial status conference (0.1, DC).				
02/12/21	Amisha Patel	0.20	L120	A105	190.00
	Correspond with C. Sarchio and K. Vinson regarding court order (0.2, DC).				
02/16/21	Mara Cusker Gonzalez	0.60	L120	A103	630.00
	Draft report to client, litigation counsel, and bankruptcy counsel regarding hearing in NY Opioids coordinated litigation regarding McKinsey Consent Order and objections to same.				
02/16/21	Lindsay Zanello	0.10	L120	A105	88.00
	Communicate internally regarding status of West Virginia case (.1).				
02/16/21	Lindsay Zanello	0.10	L120	A107	88.00
	Communicate with local counsel regarding status of WV case (.1).				
02/17/21	Mara Cusker Gonzalez	0.50	L120	A103	525.00
	Revise draft report to client and litigation and bankruptcy counsel regarding decision and order in NY coordinated litigation denying defendants' summary judgment motion regarding NY Opioid Stewardship Act.				
02/17/21	Lindsay Zanello	0.20	L120	A105	176.00
	Communicate internally regarding co-defendant's motion to dismiss in NY case.				
02/19/21	Mara Cusker Gonzalez	0.50	L120	A104	525.00
	Review filings by co-defendants in Schwartz (NY) case.				
02/22/21	Mara Cusker Gonzalez	1.50	L120	A103	1,575.00
	Draft report on status conference and trial setting update in New York coordinated litigation.				
02/25/21	Mara Cusker Gonzalez	0.20	L120	A104	210.00
	Review Order in McCallister (WV) regarding unsealing process.				
02/25/21	Mara Cusker Gonzalez	0.30	L120	A104	315.00
	Review Court notices and orders in NY coordinated litigation.				
L120 SUBTOTAL HOURS AND FEES:		9.50			9,673.50

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.161942

Invoice 1010012655
Page 4

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
L140 – Document/File Management					
02/04/21	Kurt Vinson	0.50	L140	A111	150.00
	Discuss upcoming filing to the D.C. Superior Court with A. Patel (.2); contact the clerk's office for the D.C. Superior Court regarding same (.3).				
02/12/21	Kurt Vinson	0.40	L140	A110	120.00
	Prepare and send calendar updates regarding deadlines in the DC v. Purdue matter (DC).				
L140 SUBTOTAL HOURS AND FEES:		0.90			270.00
L190 – Other Case Assessment, Development and Administration					
02/02/21	Denise Neris	0.50	L190	A101	87.50
	Monitor, review, and summarize new pleadings and motion filings in NY coordinated litigation and communicate with litigation counsel regarding same.				
02/03/21	Denise Neris	0.50	L190	A101	87.50
	Monitor, review, and summarize new pleadings and motion filings in NY coordinated litigation and communicate with litigation counsel regarding same.				
02/04/21	Denise Neris	0.50	L190	A101	87.50
	Monitor, review, and summarize new pleadings and motion filings in NY coordinated litigation and communicate with litigation counsel regarding same.				
02/05/21	Denise Neris	0.50	L190	A101	87.50
	Monitor, review, and summarize new pleadings and motion filings in NY coordinated litigation and communicate with litigation counsel regarding same.				
02/08/21	Denise Neris	0.50	L190	A101	87.50
	Monitor, review, and summarize new pleadings and motion filings in NY coordinated litigation and communicate with litigation counsel regarding same.				
02/09/21	Denise Neris	1.00	L190	A101	175.00
	Monitor, review, and summarize new pleadings and motion filings in NY coordinated litigation and communicate with litigation counsel regarding same.				
02/17/21	Denise Neris	0.50	L190	A101	87.50
	Monitor, review, and summarize new pleadings and motion filings in NY coordinated litigation and communicate with litigation counsel regarding same.				
02/18/21	Denise Neris	0.50	L190	A101	87.50
	Monitor, review, and summarize new pleadings and motion filings in NY coordinated litigation and communicate with litigation counsel regarding same.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.161942

Invoice 1010012655
Page 5

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
02/19/21	Denise Neris	0.50	L190	A101	87.50
	Monitor, review, and summarize new pleadings and motion filings in NY coordinated litigation and communicate with litigation counsel regarding same.				
02/22/21	Jefferson Holder	0.40	L190	A111	120.00
	Calendar dates for responses and submission of legal documents (0.2); review status of pending matters (0.2).				
02/22/21	Denise Neris	0.50	L190	A101	87.50
	Monitor, review, and summarize new pleadings and motion filings in NY coordinated litigation and communicate with litigation counsel regarding same.				
02/24/21	Denise Neris	0.50	L190	A101	87.50
	Monitor, review, and summarize new pleadings and motion filings in NY coordinated litigation and communicate with litigation counsel regarding same.				
02/26/21	Jefferson Holder	0.40	L190	A111	120.00
	Calendar dates for responses and submission of legal documents (0.2); review status of pending matters (0.2).				
L190 SUBTOTAL HOURS AND FEES:		6.80			1,290.00

L210 – Pleadings

02/03/21	Amisha Patel	0.30	L210	A103	285.00
	Draft joint status report to court for initial scheduling conference (0.3, DC).				
02/03/21	Amisha Patel	0.10	L210	A105	95.00
	Email with H. Coleman regarding draft joint status report (0.1, DC).				
02/03/21	Amisha Patel	0.10	L210	A108	95.00
	Correspond with counsel of record regarding draft joint status report (0.1, DC).				
02/04/21	Amisha Patel	0.10	L210	A105	95.00
	Correspondence with K. Vinson regarding joint status report filing (DC, 0.1).				
02/05/21	Mara Cusker Gonzalez	0.50	L210	A104	525.00
	Review and finalize notice of bankruptcy filing in Schwartz (NY Supreme Court, NY County).				
02/05/21	Amisha Patel	0.10	L210	A105	95.00
	Email with K. Vinson regarding filing of joint status report (0.1, DC).				
02/05/21	Kurt Vinson	0.80	L210	A111	240.00
	Assist in preparation of (.3) and file Joint Status Report to D.C. Superior Court (.5).				
02/19/21	Hayden Coleman	0.30	L210	A105	315.00
	Emails to/from Dechert team regarding Schwartz complaint filed in NY County.				

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.161942

Invoice 1010012655
Page 6

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>DATE</u>	<u>TIMEKEEPER</u>	<u>HOURS</u>	<u>TASK</u>	<u>ACTIVITY</u>	<u>AMOUNT</u>
L210 SUBTOTAL HOURS AND FEES:		2.30			1,745.00
L230 – Court Mandated Conferences					
02/16/21	Mara Cusker Gonzalez	1.50	L230 A109		1,575.00
	Attend hearing in NY Opioids coordinated litigation regarding McKinsey Consent Order and objections regarding same.				
L230 SUBTOTAL HOURS AND FEES:		1.50			1,575.00
L320 – Document Production					
02/01/21	Antonella Capobianco-Ranallo	1.80	L320 A104		540.00
	Gather documents filed under seal in McCallister v. Purdue (WV).				
02/04/21	Lindsay Zanello	0.50	L320 A105		440.00
	Confer internally regarding strategy for review of documents in connection with West Virginia case.				
02/05/21	Hayden Coleman	0.80	L320 A107		840.00
	Emails to/from local WV counsel regarding McCallister document review.				
02/08/21	Hayden Coleman	0.70	L320 A107		735.00
	Emails to/from local WV counsel regarding McCallister record review.				
L320 SUBTOTAL HOURS AND FEES:		3.80			2,555.00
L350 – Discovery Motions					
02/02/21	Sara Roitman	0.20	L350 A104		210.00
	Analyze media intervenors' communications with Special Master.				
02/02/21	Sara Roitman	0.40	L350 A105		420.00
	Communicate with Dechert team regarding strategy for responding to media intervenors' communications with Special Master.				
L350 SUBTOTAL HOURS AND FEES:		0.60			630.00
L390 – Other Discovery					
02/01/21	Danielle Torrice	0.20	L390 A111		60.00
	Review and analyze docket for the NY Coordinated Litigation to reconcile and supplement internal case files (NY, .2)				
L390 SUBTOTAL HOURS AND FEES:		0.20			60.00
TOTAL HOURS AND FEES		25.70			USD 17,893.50

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.161942

Invoice 1010012655
Page 7

VALUES ON THIS INVOICE ARE BILLED IN USD

<u>TIMEKEEPER SUMMARY:</u>				
<u>TIMEKEEPER</u>	<u>TITLE</u>	<u>RATE</u>	<u>HOURS</u>	<u>AMOUNT</u>
H. Coleman	Partner	1,050.00	3.90	4,095.00
M. Cusker Gonzalez	Partner	1,050.00	6.50	6,825.00
S. Roitman	Partner	1,050.00	1.10	1,155.00
J. Tam	Partner	975.00	0.40	390.00
A. Patel	Associate	950.00	1.10	1,045.00
M. Kim	Associate	880.00	0.60	528.00
L. Zanello	Associate	880.00	1.10	968.00
C. Boisvert	Counsel	975.00	0.50	487.50
A. Capobianco-Ranallo	Legal Assistant	300.00	1.80	540.00
J. Holder	Legal Assistant	300.00	0.80	240.00
D. Torrice	Legal Assistant	300.00	0.20	60.00
K. Vinson	Legal Assistant	300.00	1.70	510.00
D. Neris	Project Assistant	175.00	6.00	1,050.00
TOTALS			25.70	USD 17,893.50



Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
FED. ID. 23-1425587
www.dechert.com

REMITTANCE AND PAYMENT INSTRUCTIONS

For questions about payment instructions please call (215) 994-4000.

Purdue Pharma L.P.
201 Tresser Blvd.
Stamford, CT 06901

April 30, 2021
Invoice Number
1010012655

Firm Client Matter Number: 399631.161942

Client Name: Purdue Pharma L.P.
Matter Name: Municipality Suits
Electronic Billing Number: 20170001582

Professional Services Rendered Through February 28, 2021

VALUES ON THIS INVOICE ARE BILLED IN USD

TOTAL AMOUNT DUE FOR THIS INVOICEUSD 15,209.47

REMITTANCE INSTRUCTIONS

For questions about payment instruction please call (215) 994-4000

Payment by Wire or ACH

Bank Name: Citi Private Bank
Bank Address: 153 East 53rd St., New York, NY
Account Name: Dechert LLP Main Account
Account #: 759527772 | ABA #: 021272655 | Swift Code: CITIUS33

Payment by Check (U.S. Only)

Please include this remittance or print the invoice number (1010012655) in the check memo. Mail to:
Dechert LLP | P.O. Box 7247-6643 Philadelphia, PA | 19170-6643

EXHIBIT B

Expenses

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399631.178405

Invoice 1010012656
Page 41

VALUES ON THIS INVOICE ARE BILLED IN USD

DISBURSEMENTS:

<u>DESCRIPTION</u>	<u>AMOUNT</u>
Filing Fees and Related	
Vendor: File & ServeXpress, LLC; Invoice#: 202101064221401; Date: 2/1/2021 - Opioid LitigationCM#	20.00
	20.00
Court Costs	
Vendor: Matthew B. Stone; Invoice#: 021721-344105; Date: 2/17/2021 - Feb. 17 Omnibus Hearing - Court Costs - Court Solutions	70.00
Vendor: Matthew B. Stone; Invoice#: 021721-344105; Date: 2/17/2021 - Feb. 17 Omnibus Hearing - Court Costs - Court Solutions	70.00
	140.00
Westlaw Search Fees	
Westlaw Search Fees	37.89
	37.89
Pacer Research Fees	
Pacer Research Fees	221.60
	221.60
DOCKET FEES	
DOCKET FEES	40.41
	40.41
Lexis/Legal Research	
Lexis/Legal Research	706.67
	706.67
Federal Express Charges	
Federal Express Charges	191.96
	191.96
TOTAL DISBURSEMENTS	USD 1,358.53

Client Name: Purdue Pharma L.P.
Firm Matter Number: 379612.168206

Invoice 1010012651
Page 3

VALUES ON THIS INVOICE ARE BILLED IN USD

DISBURSEMENTS:

<u>DESCRIPTION</u>	<u>AMOUNT</u>
Federal Express Charges	
Federal Express Charges	14.92
	14.92
TOTAL DISBURSEMENTS	USD 14.92

Client Name: Purdue Pharma L.P.
Firm Matter Number: 379612.177870

Invoice 1010012652
Page 3

VALUES ON THIS INVOICE ARE BILLED IN USD

DISBURSEMENTS:

<u>DESCRIPTION</u>	<u>AMOUNT</u>
Legal Publication Expense	
Vendor: Stephen S. Wasserman; Invoice#: 10795; Date: 1/1/2021	99.00
	99.00
TOTAL DISBURSEMENTS	USD 99.00

Client Name: Purdue Pharma L.P.
Firm Matter Number: 399630.163596

Invoice 1010012654
Page 2

VALUES ON THIS INVOICE ARE BILLED IN USD

DISBURSEMENTS:

<u>DESCRIPTION</u>	<u>AMOUNT</u>
Consultants Fees	
Vendor: Ankura Consulting Group, LLC; Invoice#: CI-026856; Date: 2/9/2021 - Professional services rendered January 2021	201.69
	<hr/>
	201.69
TOTAL DISBURSEMENTS	<hr/>
	USD 201.69
